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CUTANEOUS MALIGNANT MELANOMA PREFACE
The word ‘melanoma’, according to Hippocrates back in the fifth century BC, 
originates from the ancient Greek adjective ‘μέλᾱς’, meaning ‘black’ and the suffix 
‘ώμᾱ’ referring to a tumor; although it was first described as a disease entity by 
René Theophile Hyacinthe Laënnec in 1812 [8].
Cutaneous Melanoma (CM) develops from malignant transformation of melanocytes, 
the pigment producing cells residing in our skin. CM is one of the deadliest types 
of skin cancer due to its high metastatic propensity. Although considerable efforts 
have been employed to effectively eliminate the disease, incidence rates of CM are 
increasing considerably worldwide. Approximately 232,100 CM cases are diagnosed 
and about 55,500 deaths are reported annually [9]. The incidence and mortality 
rates of CM vary per geographic location although the highest incidence rates are 
reported for Caucasian populations due to fair skin color [10].
Specifically in the Netherlands, melanoma of the skin is the 5th most common 
cancer type with 6,189 cases reported in 2017 as well as 796 deaths according to 
the Dutch Cancer Registry [11, 12]. Most melanoma cases are diagnosed early, at a 
localized stage and are reported with a two-year survival rate of 96% [11]. Survival 
of metastatic melanoma however, remains poor in spite of introduction of novel 
immune and targeted therapies [13]. 
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ENVIRONMENTAL RISK FACTORS AND CLASSIFICATION
To better understand CM development we may consider melanoma as a multi-factorial 
disease arising from an interplay of genetic and environmental risk factors. An 
important environmental risk factor for melanoma development is strong intermittent 
exposure to ultraviolet (UV) radiation and sunburn at a young age [14]. Artificial 
exposure to UV radiation through tanning bed sessions for cosmetic purposes may also 
be associated with an increased risk for CM development [15, 16]. UV radiation mainly 
causes genetic alterations in the skin through direct DNA damage, mainly formation 
of pyrimidine dimers, resulting in mutations that may drive malignant transformation 
of expanding keratinocytes and melanocytes [17]. At the molecular level, UV increases 
skin pigmentation through stimulation of the melanocortin 1 receptor (MC1R) on 
the surface of melanocytes by its ligand α-melanocyte-stimulating (α-MSH). This 
mediates production of melanin, the main defense mechanism against UV radiation-
induced damage [18, 19]. Germline variants in the MC1R gene are associated with fair 
skin and these individuals have a lower capacity of activating MC1R, associated with 
increased susceptibility to melanoma [20, 21].
CM may be classified into two types depending on UV-exposure duration and 
genetic signatures; The chronically affected sun-damaged areas such as head and 
neck and non-chronically affected sun damaged areas such as the trunk, legs and 
arms (CSD and non-CSD respectively) [3, 22, 23]. The most common non-CSD 
subtypes are superficial spreading melanoma (SSM) and nodular melanoma (NM) 
whereas lentigo maligna melanoma (LMM) is a common CSD subtype [24, 25]. An 
un-common sub-type of melanoma in Caucasian populations is Acral Lentiginous 
Melanoma (ALM), with only 5% reported cases. ALM is a frequent subtype of 
melanoma in Asian, African and Hispanic populations [26].
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MUTATIONAL SIGNATURE OF CM
Melanocytes are neural crest-derived cells which not only migrate to the skin 
but also different parts of the body such as the eyes and mucosal areas during 
development. [27, 28]. These melanocytes can give rise to different types of 
melanoma, including mucosal and uveal in addition to cutaneous melanoma.
Primary CMs are not only found de novo but can develop from precursor lesions 
such as a common melanocytic nevus, an atypical melanocytic nevus or a lentigo 
maligna (Figure 1). Approximately 30% of CMs are derived from a common 
melanocytic nevus, although the percentage in high-risk individuals is higher, 
reaching 50% [29, 30].
Figure 1 Genetic evolution of cutaneous melanoma. Simplistic model of genetic evolution of cutaneous 
melanoma (CM) and the underlying common genetic alterations describing precursor lesions (common 
nevus), intermediate lesions (dysplastic nevus), primary and invasive melanoma. Source data were 
adapted from the following resources: [1-4].
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A complex network of events contributes to CM development and considerable 
efforts have been employed to enhance our understanding of the different molecular 
pathways involved. The most frequently hyperactivated signaling pathway in 
melanoma development is the mitogen-activated protein kinase (MAPK) pathway 
that mediates transcription of proliferative genes and cell growth. Several oncogenes 
and tumor suppressor genes are involved in melanoma pathogenesis. The three most 
common MAPK-activating mutations in two oncogenes are BRAFV600E and NRASQ61K/R 
known to exist in a mutually exclusive pattern. Following these two oncogenes, NF1, 
seems to be the third most commonly mutated tumor suppressor gene and negative 
regulator of the MAPK-pathway according to whole exome sequencing (WES) 
analysis and functional validations (Figure 1) [31]. Also, KIT is a driver oncogene 
activating MAPK signaling in a small percentage of melanomas [32, 33]. 
Collectively, based on the significantly mutated oncogenic driver genes in melanoma, 
genomic classification reveals four sub-types and these include the BRAF subtype 
(presence of BRAF hotspot mutations), RAS Subtype (presence of RAS hotspot 
mutations), NF1 subtype (presence of NF1 loss-of-function mutations) and a triple 
wild-type (WT) subtype that lacks hot-spot BRAF, NRAS or NF1 mutations [34]. 
Starting from the common melanocytic nevus phase, recent studies provide evidence 
for clonality of BRAFV600E mutation (Figure 1) [2]. A distinct feature that distinguishes 
benign nevi from melanomas is that nevi eventually stabilize and undergo cellular 
senescence. Activation of senescence pathways in benign nevi prevents further 
cell growth. The G1/S checkpoint pathway appears to be the main mediator of 
senescence in nevi [35]. The concept of oncogene activation in nevus cells that does 
not result in tumor formation, is known as Oncogene-Induced Senescence. Benign 
nevi in the current instance enter a permanent cell-cycle arrest following the first 
BRAF mutation [36]. Several lines of evidence show that the immune system plays 
a role in regulating the apoptotic potential of benign nevi [37, 38]. A clinical study 
demonstrated a three-fold increased risk of malignant melanoma development in 
immunosuppressed transplant recipients compared to matched controls, suggesting 
a role of the immune system in preventing progression into a melanoma [39]. 
The atypical or dysplastic nevus is a genetically intermediate melanocytic lesion 
that may be difficult to distinguish from a malignant melanoma [40]. In contrast to 
benign nevi, those melanocytic lesions not only have a single activating mutation 
in BRAF but multiple driver mutations such as NRAS, TERT promoter (pTERT) 
mutations and also heterozygous alterations for tumor suppressor genes such 
as CDKN2A (Figure 1) [2]. Collectively, these data suggest that dysplastic nevi are 
indeed a distinct entity from benign nevi and melanomas based on their genetic 
make-up. It is worth noting that individuals with increased numbers of dysplastic 
nevi are also at increased risk of developing melanoma [41]. 
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Regulation of telomerase activity and telomere length has been a contributing 
factor not only for underlying features of intermediate and primary melanoma 
lesions but also in determining melanoma risk. The telomerase reverse 
transcriptase (TERT) gene encodes for a ribonucleoprotein that regulates telomere 
length and cell integrity [42-45]. The wild-type pTERT contains binding sites for 
c-Myc (E-Box), SP1, and ETS transcription factors [46]. Genetic and transcriptomic 
data suggest that increased telomere length is associated with higher melanoma 
risk and is correlated with disturbed homeostasis of telomere regulation [47]. The 
majority of pTERT mutations are found at two hotspots, in a mutually exclusive 
pattern, at –124 bp (c.1-124C>T) and -146bp (c.1-146C>T) upstream from the ATG 
start site. These mutations create ETS/TCF transcription factor binding motifs 
causing increased TERT expression [48]. Upregulation of TERT is correlated with 
presence of mutations in the promoter region and is mainly observed in primary 
and invasive stages of melanoma but not in the benign nevus phase [4]. 
The primary stage of melanoma requires additional genetic alterations and 
these are mainly centered around the impairment of G1/S checkpoint pathway 
resulting in senescence escape of melanocytic cells [4]. Specifically, loss of 
CDKN2A mainly by deletions, is a significant contributing factor leading to loss 
of p16INK4A expression in melanomas [22]. Some novel driver genes identified for 
CM by application of WGS include DDX3X, RASA2, PPP6C, RAC1 or RB1 all found to 
be specific for CM but not acral or mucosal melanomas [49]. Loss of Phosphatase 
and tensin homolog (PTEN), a key tumor suppressor gene regulating cell growth, is 
critical in facilitating melanoma development through deregulation of the PI3K/
AKT/mTOR pathway, reduction of apoptosis and promotion of cell survival [50]. 
In addition, deregulation of p53-dependent apoptotic pathways and mutations 
within tumor protein 53 (TP53) are correlated to a more advanced progressed state 
and metastatic melanoma behavior (Figure 1) [4].
Collectively, improved knowledge on the molecular pathways enhanced the 
identification of novel biomarkers to improve CM diagnosis and treatment, 
although there is still more to be uncovered. 
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PATHWAYS TO CM TREATMENT
BRAF, is a protein kinase and key regulator of the MAPK signaling pathway that is 
mutated in about 50% of CMs but also in other types of cancer including colorectal, 
leukemia and thyroid [51]. About 90% of mutations within BRAF are specific to position 
V600E, a gain of function mutation leading to a constitutively active state of BRAF and 
hyperphosphorylation of MEK thereby stimulating cancer cell growth [52].
Vemurafenib, dabrafenib and encorafenib are FDA-approved BRAF inhibitors that 
initially presented promising results in melanoma targeted therapy through inhibition 
of hyperactivation of MAPK signaling and suppression of tumor growth [53-55]. 
Nevertheless, combinatory treatment using a MEK inhibitor, trametinib, cobimetinib 
and binimetinib, against downstream components of MAPK pathway, showed delay 
in the onset of resistance and improved overall survival (OS) in phase 3 clinical trials 
[56-59]. Even though tumor reduction was observed in more than 50% of BRAFV600E 
mutated patients, in the majority of cases there was development of tumor resistance 
within 4-9 months after treatment through re-activation of MAPK pathway [60-63]. 
Still, there is little clinical evidence about guidance for the best targeted treatment of 
metastatic melanoma with limited toxic events and no relapse development [64]. 
Since targeted therapy through BRAF inhibition can only be applied in about 50% of 
patients, immunotherapies can provide effective treatment with long-term responses 
independent of the mutational status of patients [65]. This has been successful through 
the development of antibodies against immune checkpoints such as ipilimumab, 
a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA-4) which 
downregulates immune responses [66]. In addition, nivolumab and pembrolizumab 
target the programmed cell death protein 1 (PD-1), a T cell inflammatory activity 
suppressor, and showed improved OS in patients with progressed melanoma. The 
combination of CTLA-4 and PD-1 inhibitors have been proven superior to monotherapy 
in patients with PD-L1 negative tumors [67-69]. Even though there has been success 
in targeting the immune system, still future studies are required to determine the 
optimal conditions and combinations but also possibly new targets to further improve 
the outcome of patients with metastatic melanoma [70]. 
16
INSIGHT INTO GENETIC SUSCEPTIBILITY- WHAT IS 
KNOWN SO FAR
A family history of melanoma has a significant role in determining an individual’s 
risk of developing the disease. About 10-12% of reported CM cases occur in familial 
kindreds (Figure 2), therefore, familial (or hereditary) melanoma is arbitrarily defined 
by the clustering of at least two or more melanomas in first degree relatives [71]. 
High-penetrance genes have low population frequency and a higher impact on cancer 
development while, low-penetrance genes have high population frequencies but with 
a reduced effect size [72]. Several methods have been employed to identify high-
penetrance genes that may predispose to familial melanoma. 
Starting with genetic linkage analysis back in 1992 using DNA markers, scientists 
uncovered the first hint of chromosome 9p21 to be critically important in familial 
predisposition to melanoma [73]. Follow-up studies aiming to zoom into the 
chromosomal area of interest, uncovered cyclin-dependent kinase Inhibitor 2A 
(CDKN2A) as the first melanoma predisposition gene [74, 75]. A year later, a specific 
founder mutation was identified in Dutch-kindreds, a 19bp deletion in exon 2, 
known as the p16INK4A-Leiden mutation (c.225_243del, p.(A76Cfs*64)) [76]. CDKN2A 
is the most common high-penetrance melanoma susceptibility gene known today, 
not only in The Netherlands (70%) but also world-wide (40%) (Figure 2) [77].
Figure 2 Summary of currently identified candidate high-penetrance melanoma susceptibility genes. The 
first pie chart on the left represents two settings of CM where 90% of cases are found in the general population 
(sporadic) and 10% report a family history of melanoma (familial). Zooming into the familial setting, several 
high-penetrance melanoma susceptibility genes have been identified thus far with CDKN2A accounting for 
most families (40%) and several other candidate genes, each responsible for about <1% of families. There is also 
a proportion of polygenic risk factors, effect of medium and low penetrance genes (20%) but also environmental 
risk factors. There is still a proportion of unknown genetic variability in the occurrence of hereditary melanoma.
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Carriers of germline mutations in melanoma predisposition genes, such as CDKN2A, 
that may also present with increased number of atypical moles (known as dysplastic 
nevi) could be designated as Familial Atypical Multiple Melanoma Syndrome (FAMMM 
syndrome) patients [78]. FAMMM syndrome patients with germline CDKN2A 
mutations have a 70% risk of developing melanoma with the first sign of disease 
appearing at a relatively young age (mean <45 years) [79, 80]. Germline CDKN2A 
mutation carriers have an additional life-time risk of 15-20% to develop pancreatic 
ductal adenocarcinoma (pancreatic cancer; PC) [81-83]. Interestingly, clinical studies 
suggest variability in occurrence of melanoma and PC within families indicating that 
modifying factors may contribute to the risk of developing these two tumor types 
in patients with/without germline CDKN2A mutations [81, 84]. An example is the 
genetic variation in the MC1R gene, found to modify the risk of developing melanoma 
in CDKN2A-mutated families [85, 86]. Determination of genetic risk factors that 
modulate the risk of PC and melanoma in CDKN2A-mutated families, would therefore 
allow for a better identification of patients at increased risk that might benefit from 
personalized clinical management. 
CDKN2A is located on chromosome 9p21.3 and encodes for two distinct proteins 
that are translated in alternate reading frames (ARFs) from alternatively spliced 
transcripts, therefore consist of different amino acid sequences (Figure 3). The α 
transcript encodes for p16INK4A, a tumor suppressor protein that mediates G1 arrest 
by inhibiting the phosphorylation of Cyclin-D1-CDK4/6 complex [87, 88]. The 
alternative β transcript encodes for p14ARF which is also a tumor suppressor protein 
that inhibits MDM2-mediated ubiquitination thereby promoting p53-dependent 
apoptotic pathways (Figure 3) [89-92]. The p16INK4A-Leiden mutation specifically 
causes a reading frameshift resulting in truncated p16INK4A protein which loses its 
capacity to bind to CDK4/CDK6 complex and a p14ARF fusion protein that seems to 
retain functionality (Figure 3) [7]. 
The implementation of mouse models to generate knock-out (KO) mice for both 
p16INK4A and p14ARF via conventional gene-targeting approaches has also been 
successful in providing evidence for cancer development including fibrosarcoma 
and lymphoma [93, 94]. 
Combination of mutant HRAS and CDKN2A KO led to CM development in mice that 
also showed loss-of-heterozygosity (LOH) for the remaining WT allele [94, 95]. In 
addition, simultaneous inactivation of CDKN2A and Stk11 (Lkb1) loss in BRAFV600E mutant 
melanocytes induced mTORC1 and mTORC2/AKT activation leading to rapid melanoma 
formation in mice [96]. More recently, application of Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR) technology to induce genomic modifications, 
provided evidence that loss of p16INK4A protein mediates invasive behavior of melanoma 
cells in-vivo due to deregulation of the BRN2 transcription factor [97].
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Interestingly, CDKN2A function is lost in hereditary melanoma, but also in sporadic 
melanoma, commonly through deletion [22]. p16INK4A expression was significantly 
reduced in melanomas when compared to nevi according to transcriptomic data, 
suggesting that p16INK4A is the predominant tumor suppressor protein acting at the 
transition stage to invasive melanoma [4]. Bi-allelic inactivation of CDKN2A is mainly 
observed in progressed stages of the disease but about 40% of sporadic melanoma 
cases already carry a somatic mutation, chromosomal deletion and promoter 
hypermethylation in CDKN2A [34, 49]. Collectively, these data suggest a significant 
effect of both germline and somatic mutations of CDKN2A in melanoma development. 
Following CDKN2A, Cyclin-dependent kinase 4 (CDK4) is the second high penetrance 
melanoma susceptibility gene identified through a candidate gene sequencing 
approach [98]. CDK4 is less frequently mutated than CDKN2A, since it has only 
been reported in a total of 18 melanoma families up to date according to follow-up 
studies [99-102]. Besides human studies, in-vivo experiments with mice carrying 
the germline CDK4 mutation, p.R24C, revealed susceptibility to melanoma 
development after exposure to carcinogen treatment [103]. 
Figure 3 Schematic representation of CDKN2A exons and coding proteins. CDKN2A is located on 
chromosome 9p21 and encodes for two distinct tumor suppressor proteins. The 19-bp deletion of p16INK4A-
Leiden mutation is located in exon 2. The α transcript encodes p16INK4A that regulates G1/S cell cycle arrest 
by inhibiting the CDK4/6 complex. The β transcript encodes p14ARF which is involved in p53-related 
apoptotic pathways by inhibiting MDM2. The resulting p16INK4A-Leiden truncated protein disrupts G1/S 
cell cycle arrest by losing the binding capacity to CDK4/CDK6 complex. The resulting p14ARF-Leiden 
fusion protein seems to remain functional. Source data were adapted from the following resources [5-7]. 
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Due to the limitation of genetic linkage and candidate gene screening to discover 
additional novel high penetrance melanoma susceptibility genes, it was not 
until 2011, that the development of new genomic sequencing technologies were 
implemented to discover novel genes. Germline mutations in the tumor suppressor 
gene, BRCA1-associated protein 1 (BAP1), were identified in two families with atypical 
melanocytic tumors by application of sequencing technology [104, 105]. Somatic 
loss of the WT allele was detected in the tumors of patients. In addition, BAP1 loss 
increased the predisposition for other tumor types including mesothelioma, renal 
cell carcinoma and basal cell carcinoma [106-109]. Overall, germline mutations in 
BAP1 account for a small percentage of melanoma families.
Moreover, the microphthalmia-associated transcription factor gene (MITF) is the most 
well-known medium penetrance melanoma susceptibility gene. MITF regulates 
melanocyte development and differentiation, and was the first gene to be identified 
by next-generation sequencing (NGS) technology in melanoma susceptibility [110, 
111]. The MITF p.E318K germline mutation alters MITF transcriptional activity 
through abrogation of a sumoylation motif. Germline mutation carriers have also 
been associated with increased risk for renal cell carcinoma and PC [112].
The application of more advanced methods such as WES analysis had a significant 
effect on identifying high penetrance genes for melanoma. The initial variants 
identified were members of the telomerase and shelterin complex including genes 
that protect chromosomal ends. In 2013 a variant was found within the promoter of 
telomerase reverse transcriptase gene (TERT). The mutation, -57bp from the translation-
start site, segregated with disease in a 14-case melanoma family and functionally 
created a binding motif for ETS/TCF transcription factor leading to increased TERT 
expression [48]. In concordance, the pTERT mutation that was detected in a single 
melanoma-prone family, (G>A) at –246 bp upstream from the ATG start site, was 
previously associated with low telomerase activity in patients with non–small cell 
lung cancer [113]. Two-carriers with germline mutations in TERT developed several 
types of cancer, including ovarian cancer (at 27 years), melanoma (at 20 years), renal 
cell carcinoma, bladder cancer, breast cancer and finally lung cancer [48]. Collectively 
these data suggest that TERT constitutes an additional high penetrance gene for 
familial melanoma that is also mutated in sporadic cases. 
Moreover, application of whole-genome sequencing (WGS), WES and targeted 
sequencing identified loss-of-function mutations in the protection of telomeres 1 
(POT1) gene in melanoma families from the UK and Australia [114]. Six families 
were found positive for novel adrenocortical dysplasia homologue (ACD) mutations 
and four families were positive for telomeric repeat binding factor 2 interacting protein 
(TER2IP) variants including segregating nonsense mutations for both genes 
by screening 510 melanoma families [115]. Collectively these data suggest that 
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dysregulation of telomeres is an important contributing-pathway in a proportion 
of high-risk families CM families.
The most recent application of WES identified additional rare variants within the 
golgi membrane protein 1 (GOLM1) gene, EBF Transcription Factor 3 (EBF3) gene, DNA 
Polymerase Epsilon (POLE) gene and Tumor Protein P53 Regulated Apoptosis Inducing 
Protein (TP53AIP1) gene, although the effect size and functional significance of 
these variants still requires clarification by future studies [116-119]. 
To summarize, with CDKN2A mutations accounting for about 40% of variation in 
familial clustering of CM world-wide, and rare mutations in CDK4, MITF, BAP1, 
TERT, POT1, ACD, TERF2IP, GOLM1, EBF3, POLE and TP53AIP1 responsible for up to 
10% of variation, there is still about 50% unexplained remaining germline variation 
(Figure 2). The intensive clinical follow-up data in families with proven germline 
mutations may reduce the number of melanoma cases. Nevertheless, the possibility 
for an effect of polygenic risk factors such as multiple medium and low-penetrance 
genes, including MITF, MC1R, SLC45A2, ARNT and others cannot be excluded for 
these families. The shared environmental exposures of affected family members 
could also be a contributor to melanoma development (Figure 2) [120].
Combined, other rare high-penetrance genes are very likely to exist and application 
of WES and WGS analysis provide the best resource in clarifying the unknown 
genes. The identification of alterations within the regulatory region of TERT 
suggests that WGS analysis is a promising tool in uncovering variation within the 
non-coding and regulatory region of our genome. Collectively, the identification 
of novel high penetrance melanoma susceptibility genes is still essential in order 
to improve genetic testing and counselling in hereditary melanoma patients.
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IDENTIFICATION OF CANCER DEPENDENCIES AS NEW 
THERAPEUTIC TARGETS
In addition to predisposition genes and driver genes, a third class of genes is 
relevant for the biology and treatment of cancer and these are dependence/fitness/
essential genes [121]. 
Application of large-scale pharmacogenomic screens across different panels of 
cancer cell lines provides a possible solution in un-revealing novel fitness genes 
as possible biomarkers for therapy [122]. Moreover, the recent advancement of 
CRISPR-Cas9 screening technology may provide a precise method in determining 
novel biomarkers with high precision and less false-positive targets when compared 
to previously used screens through short-hairpin RNAs (shRNAs) [123, 124]. The 
CRISPR-Cas9 technique consists of using a single-guide RNA (sgRNA) molecule 
to bind to complementary DNA sequences, which simultaneously recruits the 
endonuclease Cas9 to introduce double-stranded breaks in the target DNA. The 
resulting double-stranded break is then repaired, allowing modification or removal 
of specific DNA bases. The mechanism of repair usually involves non-homologous 
end joining, an error prone pathway that results in generation of indels within the 
gene [125, 126].
Cancer in vitro systems are now being investigated using pooled CRISPR-Cas9 
screens that employ genome-scale libraries consisting of thousands of sgRNAs. 
Data from these systems can be used to identify and prioritize new cancer 
therapeutic targets firstly by infecting tumor cell lines of interest and secondly by 
measuring the endpoint sgRNA abundance to identify depleted or enriched genes 
from the screen (usually 14-21 days after infection) (Figure 4) [127-129]. 
A recent study aiming to identify targets which when knocked-out confer resistance 
to melanoma immunotherapy, showed that Apelin Receptor (APLNR) was a modulator 
of interferon-γ responses in tumors by application of CRISPR-Cas9 positive selection 
screening [130]. On a similar note, negative selection screens have a general goal in 
identifying genes which when lost have an effect on cell proliferation and therefore 
are essential for cell fitness [127].
Genes may influence the fitness of melanoma cells either because they encode 
proteins involved in essential cellular processes, or they are required for viability 
specifically of cells of the melanocytic lineage. Still, the identification of context-
specific fitness genes to therapeutically target for maximal clinical benefit of 
melanoma patients remains a challenge [129]. Collectively, these data suggest that 
application of CRISPR-Cas9 screening technology may provide a precise method 
in determining novel vulnerabilities for melanoma targeted therapy. 
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Figure 4 Schematic overview of a CRISPR-Cas9 knockout screen. The cell-lines of interest (different 
cancer lineage) are infected by the human library of sgRNAs knocking out all known genes (Genome 
Scale CRISPR Knock-Out library). The sgRNA abundance is read using Next Generation Sequencing 
technology at days 0 and 14 (or 21) after infection. Those sgRNAs that are depleted compared to the 
initial sgRNA abundance depict genes essential for cell growth whereas sgRNAs that are enriched 
indicate genes that may serve as possible tumor suppressors.
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OBJECTIVES 
This thesis sought to investigate different aspects of CM biology, mostly linked to 
genetic dependencies in hereditary and sporadic melanoma. Specifically, herein 
we have employed state of the art technologies such as WES, digital PCR (dPCR) 
and CRISPR-Cas9 genetic engineering to unravel the complexity of genetic events 
in hereditary and sporadic melanoma. Specific objectives include: 
a) Identification and validation of novel high penetrance melanoma 
susceptibility genes. 
b) Identification of genetic modifiers predicting the risk of melanoma and 
PC in p16INK4A-Leiden mutation carriers.
c) Timing of CDKN2A loss-of-heterozygosity in melanocytic tumors of 
p16INK4A-Leiden mutation carriers.
d) Determination of genetic dependencies in melanoma by analyzing and 
processing CRISPR-Cas9 screening technology data.
To elucidate the genetic basis of familial melanoma and discover novel high 
penetrance melanoma susceptibility genes, in chapter 2, we applied WES in 
a Dutch melanoma family. The results of WES analysis were also validated in 
available patient’s tissues and functionally verified in-vitro using cancer cell lines. 
This work is absolutely essential to improve genetic testing and counselling of 
familial melanoma kindreds since about 50% of genetic variation underlying 
genetic variability remains unknown. 
Identification of genetic risk factors, other than a germline CDKN2A mutation, 
responsible for PC and melanoma risk in CDKN2A-mutated families has been a 
challenge. In chapter 3, we sought to investigate a variable genomic region (SNP) 
within TERT/CLPTM1L high-cancer risk locus as a modifying genetic risk factor for 
PC and melanoma in p16INK4A-Leiden mutation carriers.
Even though scientific studies provide evidence for CDKN2A bi-allelic loss to be 
an important event in the transition to invasive melanoma in sporadic cases, there 
is little or no evidence known about inactivation of this tumor suppressor gene in 
the progression stages of hereditary melanoma. Therefore, in chapter 4, we sought 
to investigate CDKN2A inactivation through LOH by applying dPCR in FAMMM 
syndrome patients, carrying a germline CDKN2A mutation. Utilization of dPCR 
assays allows for numerous applications such as quantitative detection of mutant 
cell fraction in a population of ad-mixed cells, LOH and quantification of T-cells 
in tumors (Figure 5) [131-133]. In cases where quantification of the actual mutation 
of interest is challenging, dPCR technology may be applied to target a common 
polymorphic region (SNP) that is linked to the specific mutation site. This could 
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be depicted by the high probability that the SNP-allele linked to the mutation, will 
end up in the same droplet as the mutant-allele (Figure 5). Application of SNP-
based dPCR technology in melanocytic neoplasms of FAMMM syndrome patients 
allowed for absolute quantification of allelic imbalance within CDKN2A, indicative 
of LOH. We also attempted to deduce the order of genetic events via quantifying 
cells with BRAFV600E mutation, pTERT mutations and chromosome 9q LOH. 
Figure 5 Diagram of SNP-based digital PCR (dPCR) analysis. The sample of interest is partitioned into 
20,000 droplets which are then detected for the specific target of interest. The homozygous genotype for 
a wild-type (WT) sequence is depicted by a droplet positive for the green target only. The heterozygous 
genotype is depicted by positivity for the WT-allele (green), the mutant (MT) allele (blue) and the SNP-
allele (purple) that is linked to the mutation. The homozygous genotype for the mutation is depicted 
by positivity for the MT allele (blue) and the SNP-allele (purple). In cases where the mutation is not the 
direct target of amplification, targeting of the SNP allele linked to the mutant allele allows for direct 
quantification of the mutation allele frequency (AF) and therefore loss-of-heterozygosity (LOH). In the 
example shown, mutation AF was calculated by dividing the SNP-allele counts (10) over the total allele-
counts (19). The mutation AF was 53% depicting LOH in this example (>50%).
Finally, resistance to BRAF inhibitors warrants screening for identification of novel 
pathways to melanoma treatment. The application of CRISPR-Cas9 screening 
technology is nowadays the leading tool in revealing novel genetic vulnerabilities 
in cancer. Therefore, in chapter 5 we performed comparative analysis using 
bioinformatic tools to study CRISPR knockout (KO) screening data and identify 
novel fitness genes in melanoma. 
Collectively, through application of novel genomic techniques in this thesis, we hope to 
have explored in detail the genetic dependencies in familial and sporadic melanoma.
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ABSTRACT
A proportion of patients diagnosed with cutaneous melanoma reports a positive family history. 
Inherited variants in CDKN2A and several other genes have been shown to predispose to 
melanoma; however, the genetic basis of familial melanoma remains unknown in most cases. 
The objective of this study was to provide insight into the genetic basis of familial melanoma. 
In order to identify novel melanoma susceptibility genes, whole exome sequencing (WES) 
analysis was applied in a Dutch family with melanoma. The causality of a candidate variant 
was characterized by performing co-segregation analysis in five affected family members 
using patient-derived tissues and digital PCR analysis to accurately quantify mutant allele 
frequency. Functional in-vitro studies were performed to assess the pathogenicity of the 
candidate variant. Application of WES identified a rare, nonsense variant in the NEK11 gene 
(c.1120C>T, p.Arg374Ter), co-segregating in all five affected members of a Dutch family. NEK11 
(NIMA-Related Kinase 11) is involved in the DNA damage response, enforcing the G2/M cell 
cycle checkpoint. In a melanoma from a variant carrier, somatic loss of the wildtype allele of 
this putative tumor suppressor gene was demonstrated. Functional analyses showed that the 
NEK11 p.Arg374Ter mutation results in strongly reduced expression of the truncated protein 
caused by proteasomal degradation. The NEK11 p.Arg374Ter variant identified in this family 
leads to loss-of-function through protein instability. Collectively these findings support NEK11 
as a melanoma susceptibility gene. 
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Cutaneous melanoma is an aggressive type of skin cancer resulting from malignant 
transformation of melanocytes. Incidences of melanoma continue to rise steadily, 
with more than 230,000 cases diagnosed each year worldwide, accompanied by 55,000 
deaths [1]. Ten percent of cases are found in people with familial predisposition, i.e. 
families with at least two first degree relatives with melanoma [2].
Several high-penetrance melanoma susceptibility genes have been identified 
and account for approximately 40% of melanoma families [3, 4]. The majority of 
these families are affected by germline mutations in CDKN2A [5], a key cell-cycle 
checkpoint regulator and first reported high-penetrance melanoma susceptibility 
gene [6-8]. Following CDKN2A, germline mutations in other genes have been linked 
to familial predisposition to melanoma; these include CDK4 [9] and BAP1 [10, 11]. 
Bi-allelic inactivation has been reported in tumor tissues with germline variants in 
BAP1 including mesothelioma, uveal melanoma and cutaneous melanoma [12, 13] 
suggesting genetic analysis is an informative approach for discovering melanoma-
predisposition genes. Considering the discovery of germline MITF variants, 
functional analysis revealed mutant MITF to have increased transcriptional 
activity, migration and invasion in melanoma cell lines [14, 15] suggesting that 
not only genetic analysis in patient’s tissues but also functional validation adds to 
the current value of mutation screening. Application of Whole Exome Sequencing 
(WES) analysis has been successful in identifying rare variants including TERT 
promoter [16], POT1 [17] TERF2IP and ACD [18], GOLM1 [19], EBF3 [20] and POLE 
[21] as candidate high-penetrance melanoma susceptibility genes. Still, the 
genetic basis of over half of melanoma families remains unknown, impairing 
genetic testing and counselling in families with predisposition to melanoma [22, 
23]. Here, NEK11 gene was identified by WES in a Dutch family with melanoma and 
characterized as a potential novel high-penetrance melanoma-susceptibility gene. 
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METHODS
Whole exome sequencing (WES)
Study population and ethics approval 
WES was carried out in blood-derived DNA samples of two members of a Dutch 
familial melanoma family. Study approval was obtained by the ethics committee of 
Leiden University Medical Center (LUMC, P00.117).
Sequencing analysis and bioinformatics 
Sequencing was performed on Hiseq2000 platform with TruSeq Exome Enrichment 
kit. Paired-end reads of 110 bp were generated with mean coverage of 40X. The 
Burrows-Wheeler aligner was used for mapping sequencing reads to the reference 
UCSC human genome. SNVs were detected using samtools/bcftools. Indels were 
detected with Pindel and annotated to dbSNP144 using ANNOVAR. Variants 
altering the coding sequence were selected excluding those that were present at a 
frequency of 0.0005% or higher in the Kaviar (Known VARiants) control population 
database, including 162 million variants from human genomes of datasets such as 
ExAc and 1000Gs [24]. 
Selection, validation and interpretation of variants
Variants identified were assessed to identify pathogenic or potentially pathogenic 
variants in ClinVar. Variants were then filtered using in-silico prediction 
algorithms to show if an alteration affects protein function. Details about criteria 
for interpretation of variants has been reported previously [25]. These included 
exonic, frameshift, non-synonymous SNVs, splicing and stop-gain SNVs. We then 
focused on segregating mutations between all family members and functional 
significance. Co-segregation of NEK11 p.Arg374Ter mutation was confirmed 
using Sanger sequencing of germline DNA from family members 1, 4 ,5, 7 and 12 
(Supplemental Table 1) (Macrogen, Amsterdam, The Netherlands).
Genotyping and LOH analysis
DNA was extracted from primary melanoma FFPE tissue of a NEK11 p.Arg374Ter 
mutation carrier (family member 5) using the QIAamp DNA FFPE Tissue kit 
(QIAGEN, Venlo, The Netherlands) according to manufacturer’s instructions. DNA 
extraction of normal and tumor tissue was obtained through micro-dissection/
punch biopsy by the pathology department of LUMC, The Netherlands. Genomic 
primer sets were used to amplify the region of interest containing the mutation 
(NEK11 c.1120C>T) and a common SNP (rs4974475, chr3:130882827, MAF 17%), 
located at 2 kb upstream from the NEK11 mutation site to verify LOH (Supplemental 
Table 1). PCR products were cleaned-up using a PCR clean-up protocol (Bio-Rad, 
Hercules, California, USA) and sequenced by Sanger sequencing analysis-long run 
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(Macrogen, Amsterdam, The Netherlands). Chromatograms were then analyzed by 
Chromas Technelysium DNA Sequencing Software (Technelysium Pty Ltd, South 
Brisbane, Australia).
Digital PCR analysis (dPCR)
Mutation detection assays specific for dPCR (Bio-Rad, Hercules, California, USA) 
describe the incorporation of both wild-type and mutated targets in a single dPCR mix. 
In this case, the assay was designed for the detection of NEK11 p.Arg374Ter mutation. 
Detailed protocol of mutation detection dPCR assay has been described previously 
[26] and dPCR sequence information is provided in Supplemental Table 1. QuantaSoft 
software (Bio-Rad, Hercules, California, United States) was used to analyze the data 
by calculating the concentration of the amplified dPCR product (copies/μl) [26]. The 
wild-type (WT) allele frequency was calculated by dividing the WT allele counts over 
the total allele counts and the mutant (MT) allele frequency was calculated by dividing 
MT allele counts over the total allele counts. 
Cell culturing and maintenance
U2OS (human osteosarcoma tumor cell line) and FM6 (human cutaneous malignant 
melanoma cell line) cells were maintained in DMEM medium supplemented with 
penicillin (100 I.U./mL)/streptomycin (100 μg/mL) and 10% Fetal Bovine Serum 
(FBS) and glutamax 100x (Thermo Fisher Scientific, Waltham, Massachusetts, 
United States). All cells were grown in a humidified incubator at 37oC and 5% CO2 
and routinely sub-cultured when reaching 95% confluency. 
Plasmid construction and introduction of NEK11 p.Arg374Ter mutation 
NEK11-FL (full-length isoform [27]) was expressed from a plasmid construct 
containing WT NEK11 cDNA, fused with N-terminal FLAG-epitope tag (Kind gift 
from professor Andrew Fry, University of Leicester, UK) for expression in U2OS 
and FM6 cells [27]. Site-directed mutagenesis was applied to introduce NEK11 
p.Arg374Ter mutation in flag-tagged NEK11 expression vectors. Primer-sets 
were designed specifically targeting the mutation site of NEK11 exonic sequence 
(Supplemental Table 1). Thermal cycling was performed to introduce the mutation 
consisting of 1-minute denaturation at 95oC, followed by 10 cycles of 1-minute 
steps at 95oC, 63oC and 68oC. The PCR product was then digested with DpnI enzyme 
and transformed into Top10 bacteria to produce inducible vectors for functional 
experiments. Sequences of both NEK11 WT and MT expression vectors were 
confirmed by Sanger Sequencing analysis long-run (Macrogen, Amsterdam, The 
Netherlands) (Supplemental Table 1). 
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Lentivirus production
NEK11 WT and MT cDNAs were re-cloned into a lentiviral backbone containing the 
neomycin resistance gene. Lentiviral stocks were produced by transfections into 
HEK-293T cells as described previously [28] but calcium phosphate was replaced 
with polyethylenimine (PEI) in the transfection mix. Virus was quantified by 
antigen capture enzyme-linked immunosorbent assay (ELISA) measuring HIV p24 
levels (ZeptoMetrix Corp., New York, NY, USA). 
Transient transfections 
U2OS cells were harvested and seeded in appropriate growth medium in 6-well 
plates (0.5x105 cells/ml) and 60-mm dishes (1.8x105cells /ml). The DNA mix was 
prepared as follows: 0.8μg pLV-NEO-NEK11-WT, pLV-NEO-NEK11-MT and pLV-NEO-
empty lentiviral vectors (see lentivirus production section), 0.1μg Tomato-Red, 
300ng of GFP expression vector and 0.2μg pSuper. The PEI mix was prepared as 
follows: 3:1 PEI (3 parts of PEI to 1 part of DNA concentration) diluted in Gibco™ 
Opti-MEM™ Reduced Serum medium (Thermo Fisher Scientific, Waltham, 
Massachusetts, United States). PEI mix was added slowly to DNA mix followed by a 
short vortex. The mixture was kept at RT for 20 minutes and then added dropwise 
to U2OS cells. Growth medium was replaced 16 hours after transfection and U2OS 
cells were further incubated for another 24 hours. 
Lentiviral transductions
Fresh culture media were prepared with viral supernatants supplemented with 
8 μg/ml polybrene (Sigma-Aldrich, St. Louis, Missouri, United States). FM6 
cells were seeded in 6-well plates at a density of 2x105 cells/well. FM6 cells were 
incubated with virus-containing medium overnight, after which the cells were 
refed with fresh medium containing G418 (Sigma-Aldrich, St. Louis, Missouri, 
United States) to produce stable cell lines expressing NEK11 WT and MT by using 
neomycin as selection marker.
RNA isolation, cDNA synthesis and gene expression analysis 
Lymphocytic RNA of a NEK11 p.Arg374Ter carrier (family member 18) and a non-
relative spouse was isolated using the RNeasy micro kit from QIAGEN (Venlo, The 
Netherlands). RNA was isolated from FM6 cells using the SV total RNA isolation kit 
(Promega, Fitchburg, WI, USA). First strand cDNA synthesis was carried out using 
the iScriptTM c-DNA synthesis kit (Bio-Rad, Hercules, California, USA) and Sanger 
Sequencing analysis (LGTC, LUMC, The Netherlands) was used to detect presence 
of NEK11 WT and MT alleles (Primer sequences shown at Supplemental Table 1). 
NEK11 gene expression was confirmed using SYBR® green based quantitative PCR 
on CFX384 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, California, 
USA) (Supplemental Table 1). Gene expression results were analyzed using Bio-Rad 
CFX Manager 3.1 Software (Hercules, California, USA) and corrected relative to 
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reference gene expression (CAPNS1 and SRPR) as well as transfection efficiency 
target Tomato-Red (Supplemental Table 1). 
Immunofluorescence staining
Transfected U2OS cells on cover slips were washed twice in phosphate-buffered 
saline (PBS) solution and fixed with 4% paraformaldehyde (PFA) for 10 minutes. Cover 
slips with U2OS cells were then incubated for 10 minutes in PBS/0.2%Triton-X100 
(permeabilization) and pre-incubated for 30 minutes in PBS/0.05% Tween-20 
containing 5% normal goat serum (NGS). Subsequently, U2OS cells were incubated 
with monoclonal anti-flag M2 Catalog Number F1804 (Sigma-Aldrich, St. Louis, 
Missouri, United States) diluted in PBS/Tween/NGS (1:500) for 60 minutes at 
room temperature followed by washing three times in PBS/Tween for a total of 
15 minutes. The secondary antibody, anti-Mouse IgG-Cy2 (#115-225-146, Jackson 
ImmunoResearch Laboratories, Cambridge, UK) was diluted in PBS/Tween/NGS 
(1:100) and added at room temperature in the dark. U2OS cells were finally washed 
for 10 minutes with PBS/Tween and coverslips were placed on slides for analysis on a 
Leica DMRA fluorescent microscope (Nijmegen, The Netherlands). 
Drug Treatments 
MG132 proteasome inhibitor (Sigma-Aldrich, St. Louis, Missouri, United States) 
was added to U2OS and FM6 cells at a final concentration of 20 μΜ for 5-6 
hours before RNA and protein isolation procedures. The cycloheximide (CHX), 
translation inhibitor, was added at a concentration of 50μg/ml (Sigma-Aldrich, St. 
Louis, Missouri, United States) to FM6 stable-cell lines expressing NEK11 WT and 
NEK11 MT as a time-course treatment of 0, 1, 2 and 4 hours. 
Protein isolation and Western Immunoblotting analysis
U2OS and FM6 cells were washed twice in ice-cold PBS and incubated on ice for 
10 minutes in Giordano buffer (50mM Tris-HCl pH7.4, 250mM NaCl, 0.1% Triton 
X-100 and 5mM EDTA; supplemented with phosphatase and protease inhibitors). 
Lysates were collected by scraping and centrifuged at max speed for 10 minutes and 
protein concentration was determined using the Bradford method. Western Blot 
procedure was followed as described previously [29]. NEK11 protein was detected 
by the Anti-Flag antibody (1:1000) (Sigma-Aldrich, St. Louis, Missouri, United 
States) and the controls were detected by Anti-USP7 (1:1000) (Bethyl Laboratories, 
Biomol, Montgomery, Texas, USA), Anti-GAPDH (1:1000) (Sigma-Aldrich, St. 
Louis, Missouri, United States) and Anti-P53 (1:1000) (Santa Cruz Biotechnology, 
Heidelberg, Germany). After transient expression, protein levels were determined 
using the Odyssey machine (LI-COR, Lincoln, Nebraska, United States) and 
analyzed using Odyssey software according to manufacturer’s instructions. 
Secondary antibodies used were IRDye® 800CW Goat anti-Mouse IgG (H + L), 
0.1 mg (1:5000) and IRDye® 680LT Goat anti-Rabbit IgG (H + L), 0.1 mg (1:5000) 
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(LI-COR, Lincoln, NE, United States). Due to low protein expression in stably-
transduced FM6 cells, the ChemiDoc Imaging System was used to detect proteins 
with increased sensitivity and specificity. The bands were analyzed with Image 
lab software (Bio-Rad, Hercules, California, USA) according to manufacturer’s 
instructions. Protein-expression quantification was performed relative to 
unaffected expression of controls (GAPDH, USP7). 
Statistical Analysis
All data were analyzed by calculating the mean and standard deviation (SD) and 
graphs were obtained in GraphPad Prism version 7 (GraphPad software, San Diego, 
CA, USA). ANOVA and multiple comparisons were applied to detect statistically 
significant differences between expression patterns of three independent 
experiments (n=3). Statistical significance was reached when p<0.05. 
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WES analysis and identification of NEK11 p.Arg374Ter
A Dutch melanoma family presented four melanoma cases and one uveal melanoma 
case with prostate cancer. The diagnosis of melanoma in five members in multiple 
generations strongly suggests an autosomal dominant mode of inheritance 
(Figure 1) and members were negative for mutations in established melanoma 
susceptibility genes (CDKN2A, BAP1, POT1, TERT, TERF2IP, ACD, MITF, GOLM1, 
EBF3). A WES analysis was carried out on DNA from blood cells of two affected 
members (Figure 1). Among a total of 19 rare, co-segregating non-synonymous 
variants that met our criteria, 17 were missense mutations, probably damaging, 
predicted deleterious [30, 31]. These variants however, are not plausible candidate 
melanoma susceptibility genes (Table 1) since there is no evidence supporting a 
strong tumorigenic effect based on published literature. Interestingly, two were 
nonsense stop-gain single nucleotide variants (SNVs) (Table 1). One candidate stop-
gain variant was p.Arg66Ter in ZNF192, a gene possibly regulating transcription. 
However, no implications in cancer have been mentioned in published literature. 
In contrast, the other candidate was a truncating variant (p.Arg374Ter) in the 
never in mitosis-gene A (NIMA)-related kinase 11 (NEK11). This family of proteins 
functions in different aspects of cell cycle regulation, although the in-depth role of 
NIMA-related kinases remains to be uncovered [32]. NEK11 has been reported to be 
somatically mutated in different types of cancer, including lung, breast, prostate 
and melanoma [33]. The frequency of NEK11 mutations was >5% in melanomas [34, 
35] suggesting a plausible candidate in melanoma development. 
Sanger sequencing confirmed NEK11 p.Arg374Ter to co-segregate within four 
cutaneous melanoma cases and one uveal melanoma case in this Dutch melanoma 
family (Figure 1). Family members 13 and 16 were also found to be NEK11 p.Arg374Ter 
carriers although with no clinical presentation of cancer/melanoma. Considering 
the current age of these individuals and absence of the melanoma phenotype, the 
possibility for non-penetrance is very likely (Figure 1). Somatic loss of the wildtype 
(WT) allele was detected in primary cutaneous melanoma tissue of a mutation carrier 
(Figure 2A-C) and confirmed by the highly sensitive and quantitative method, digital 
PCR (dPCR) [36] whereby, a higher fraction of NEK11 p.Arg374Ter mutant (MT) than 
NEK11 WT allele was detected in melanoma tissue when compared to normal tissue 
micro dissected from the same biopsy sample (Figure 2D). Furthermore, examination 
of a common SNP (rs4974475, chr3:130882827, MAF 17%), showed loss of this variant 
in the melanoma tissue of a NEK11 p.Arg374Ter carrier, suggesting LOH over a longer 
genetic region (Supplemental Figure 1). Collectively, these data suggest a potential 
loss-of-function (LOF) mutagenic effect of NEK11 p.Arg374Ter.
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Figure 1 Co-segregation of NEK11 p.Arg374Ter in a Dutch melanoma family. Whole-exome sequencing 
was carried out for family members 1 and 4. Co-segregation of NEK11 p.Arg374Ter was confirmed by 
analyzing germline DNA from all family members. Current age and age at death of deceased individuals 
(those reported) are indicated. Age at diagnosis of each tumor type is noted in affected family members 
(M = melanoma, UM= uveal melanoma, PC= prostate cancer).
Figure 2 LOH analysis of a NEK11 p.Arg374Ter mutation carrier. Chromatogram showing DNA sequence 
of A) healthy family member (14), B) a NEK11 p.Arg374Ter carrier (family member 5) and C) tumor of 
a NEK11 p.Arg374Ter carrier (family member 5). Arrows indicate the NEK11 p.Arg374Ter mutation site. 
D) dPCR NEK11 mutation assay showing the NEK11 wildtype (WT) and NEK11 p.Arg374Ter (MT) allele 
frequency detected in normal and tumor tissue from FFPE derived DNA of family member 5. 
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Table 1 Summary of Whole-exome sequencing (WES) analysis and identification of segregating novel 
predicted damaging/deleterious variants in a Dutch melanoma family.
Gene Change Ch Ref Alt Typea SIFT Polyphen MAFb 
GPATCH3 p.Gly131Arg 1 C T missense deleterious probably_
damaging
0.00006168
ATPIF1 p.Arg94His 1 G A missense deleterious probably_
damaging
0.00004406
KALRN p.Ser1629Cys 3 C G missense deleterious probably_
damaging
0.00002641
NEK11 p.Arg374Ter 3 C T stop-gained 0.00002641
ZNF192 p.Arg66Ter 6 C T stop-gained 0.000008791
GPR111 p.Ser168Arg 6 T A missense deleterious probably_
damaging
0.00006486
GPAM p.Pro403Thr 10 G T missense deleterious probably_ 
damaging
0.000008794
NELL1 p.Val755Met 11 G A missense deleterious probably_
damaging
0.0002261
KRT77 p.Asp316Asn 12 C T missense deleterious probably_
damaging
0.00001502
OAS2 p.Tyr269Cys 12 A G missense deleterious probably_ 
damaging
-
DNAJC3 p.Arg346Gln 13 G A missense deleterious probably_
damaging
0.0001553
TEP1 p.Arg1386Trp 14 G A missense deleterious possibly_
damaging
0.001266
PLCB2 p.Arg253Trp 15 G A missense deleterious probably_
damaging
0.001074
DNASE1 p.Ala168Val 16 C T missense deleterious possibly_
damaging
0.001402
BFAR p.Phe53Ile 16 T A missense deleterious possibly_
damaging
-
ITGB4 p.Arg556Cys 17 C T missense deleterious possibly_
damaging
0.0006357
PSG7 p.Trp67Ser 19 C G missense deleterious probably_
damaging
0.0001473
GPR50 p.Gly93Ala X G C missense deleterious possibly_ 
damaging
0.00001240
GABRQ p.Arg254Cys X C T missense deleterious probably_
damaging
0.00007713
a Variants characterized by ExAC/gnomAD/Genome of The Netherlands/Ensembl databases
b MAF in European (Non-Finnish) population
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Functional analysis of NEK11 p.Arg374Ter 
Following genetic characterization of NEK11 p.Arg374Ter as a potential LOF mutation, 
functional analyses were performed to investigate the effects of this truncating 
mutation on the expression level of NEK11 mRNA and NEK11 protein. Upon transient 
transfection of NEK11 expressing plasmids in osteosarcoma tumor cell line U2OS 
the expression of NEK11 MT mRNA was lower than NEK11 WT mRNA, although the 
difference was statistically not significant (Supplemental Figure 2). U2OS cell-line 
provided the ideal conditions for functional analysis since it is an easily transfectable, 
fast-growing cell line and has been previously used to functionally characterize NEK11 
[27, 37, 38]. NEK11 MT mRNA expression was detected in lymphocyte mRNA of a 
mutation carrier by Sanger sequencing and dPCR analyses (Figure 3A-C) suggesting 
that the premature stop codon does not result in significant transcript degradation by 
nonsense-mediated mRNA decay (NMD). Combined with the finding that the mutant 
NEK11 mRNA was detected in U2OS cells (Supplemental Figure 2), these results 
indicate no significant effect of the mutation on NEK11 mRNA expression levels.
Introduction of p.Arg374Ter mutation in the NEK11 expression vector, resulted in 
synthesis of a truncated NEK11 protein lacking the whole C-terminal PEST-like 
domain as well as part of the coiled-coil motifs (Supplemental Figure 3A). The 
coiled-coil region regulates protein activation suggesting that loss or absence 
of these motifs would affect protein function [39]. The truncated protein runs 
at approximately 45 kDa, which reasonably fits with the size of 373 amino acids 
(Supplemental Figure 3A). Immunoblot analysis of protein lysates made from 
transfected U2OS cells showed that the level of the truncated protein was 3-fold 
lower than NEK11 WT expression (p<0.005; Figure 4A and B) when corrected for 
mRNA expression. Treatment with the proteasome inhibitor MG132 increased 
NEK11 protein level, particularly of the truncated product (~ 2 fold). Still, the 
difference between NEK11 WT and MT protein levels in lysates of MG132-treated 
U2OS cells is significant (p<0.005). Collectively, statistically significant lower 
protein expression was correlated with the NEK11 p.Arg374Ter mutation. 
Since a distinct subcellular localization of NEK11-FL (645 amino acids) and NEK11-S 
(450 amino acids) has been reported [27], which might affect the protein expression 
level, the subcellular localization of the Flag-tagged NEK11 MT was investigated 
in comparison to Flag-tagged NEK11-FL. Interestingly, both proteins were mainly 
localized in the nucleus of U2OS cells (Supplemental Figure 3B), in contrast to 
the earlier publication. However, in that publication GFP-tagged constructs were 
used. Indeed, using the same GFP-tagged constructs the subcellular localization 
of NEK11-FL and NEK11-S was as reported; the GFP-NEK11 MT protein localized in 
the nucleus, similar to GFP-NEK11-S (data not shown). 
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Figure 3 NEK11 wildtype and NEK11 p.Arg374Ter mRNA analysis. Chromatogram showing sequence from 
cDNA of A) healthy family member 14, and B) a NEK11 p.Arg374Ter carrier (family member 18) Arrows 
indicate the NEK11 p.Arg374Ter mutation site. C) Allele frequency of NEK11 wildtype (WT) and NEK11 
p.Arg374Ter (MT) detected by dPCR NEK11 mutation assay using DNA and cDNA from family member 18. 
Figure 4 Expression of NEK11 wildtype and p.Arg374Ter in U2OS cells. A) Lysates of U2OS cells 
transiently transfected with NEK11 wildtype (WT) , NEK11 p.Arg374Ter (MT) and pLV-empty expression 
plasmids were either untreated or treated with MG132. NEK11 was detected with anti-Flag antibody. 
GAPDH was determined as a loading control. B) Expression was calculated relative to GAPDH for each 
independent experiment and corrected for mRNA expression of NEK11. Data shown represent mean 
expression from 3 independent experiments. Error bars represent Standard Deviation (SD). Statistical 
significance is shown as *p<0.05, **p<0.005.
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Figure 5 NEK11 protein expression and quantification in stably-transduced FM6 cells. A) Western blot 
analysis of cell lysates extracted from stably transduced FM6 cells, either untreated or treated with 
MG132. NEK11 was detected using anti-Flag antibody. USP7 was detected as a loading control. B) Protein 
expression quantifications. Expression was calculated relative to USP7 for each independent experiment 
and corrected for mRNA expression. C) Effect of MG132 on NEK11 wildtype (WT) and p.Arg374Ter (MT) 
expression. NEK11 WT and MT expression was set to 1 and the log10 relative expression to USP7 is shown. 
Unpaired t-test was performed for statistical significance. Experiments performed in duplicates. Error 
bars represent Standard Deviation (SD). Statistical significance is shown as *p<0.05, **p<0.005. 
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Since transient overexpression yields very high expression levels which might partly 
mask normal regulation of NEK11 protein expression, a putative difference in protein 
expression of the NEK11 WT and the NEK11 MT was studied in more detail in stably-
transduced, disease-relevant FM6 cutaneous melanoma cells. Strikingly, NEK11 MT 
protein expression was hardly detectable with 6-fold difference compared to NEK11 
WT when corrected to mRNA levels (p=0.0024) (Figure 5A and B). Furthermore, 
treating FM6 cells with MG132 strongly increased NEK11 MT protein level (Figure 5C), 
while the effect of MG132 on NEK11 WT levels was much less pronounced, suggesting 
that the truncated NEK11 protein is prone to faster protein degradation. To examine 
protein half-life of the NEK11 WT and MT proteins, we decided to treat these FM6 
cells with the protein translation inhibitor cycloheximide (CHX) and harvest at 
different time-points. The NEK11 WT protein appeared to be a stably expressed 
protein with half-life of approximately 4 hours, in contrast to the NEK11 MT protein 
showing a half-life of approximately 1 hour in FM6 cells (Figure 6A-C). Collectively, 
we provide evidence that the NEK11 p.Arg374Ter mutation leads to the synthesis of a 
truncated protein with a very short half-life, suggesting a LOF mutation, supporting 
a tumor-suppressive role for NEK11 in familial melanoma.
Figure 6 NEK11 protein half-life analysis in FM6 cells using cycloheximide (CHX) treatments. Time-course CHX 
treatments of FM6 cells expressing A) NEK11 wildtype (WT) and B) NEK11 p.Arg374Ter (MT). USP7 was detected 
as a loading control and P53 as a positive control. C) Quantification of NEK11 WT and MT corrected for USP7 
expression over different time-points of CHX treatments. Error bars represent Standard Deviation (SD). Pearson 
R squared correlation value was 0.82. Statistical significance is shown as *p<0.05, **p<0.005, ***p<0.0005. 
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DISCUSSION
Here, a novel nonsense protein truncating variant in NEK11 p.Arg374Ter was 
identified as a possible familial melanoma predisposition mutation in a Dutch 
family. The possibility of any other potentially damaging variants found by WES in 
this family to either be causal or contributing to the melanoma-risk of this family 
was considered. Since not enough scientific evidence was available to support a 
contributing role, these variants were not investigated further.
NEK11 has been initially characterized as a DNA-damage response kinase with two 
isoforms, the full-length isoform consisting of 645 residues (NEK11-FL) and the short 
isoform consisting of 470 residues (NEK11-S) [37]. A regulatory effect during IR-
induced G2/M cell-cycle arrest has been described, i.e. NEK11 was shown to be involved 
in phosphorylation of CDC25A triggering its degradation and ultimate blocking of 
progression into mitosis [27, 38, 40]. NEK11 has been described to (de) regulate G2/M 
cell-cycle arrest in colorectal carcinoma and low expression was observed at late-
advanced stages of the disease [27, 40]. Furthermore, decreased NEK11 mRNA levels 
have also been associated with drug resistance in ovarian cancer cells [41] supporting 
that NEK11 may prevent metastatic progression in ovarian cancer. Collectively, these 
results point towards a putative tumor suppressive role of NEK11. 
NEK11 expression follows a cell-cycle dependent manner with a peak at G2/M 
phase [38] and mRNA expression is found in the brain, uterus and lungs with 
moderate expression in melanoma (median expression = 6) [42, 43]. No significant 
difference in expression between benign nevi and melanomas can be observed 
[34], however, cutaneous melanoma patients with higher NEK11 expression have 
slightly improved survival, although this association is not statistically significant 
[44]. Moreover, NEK11 has been suggested to play a role in the G1/S checkpoint in 
association with NEK2, however, the exact mechanism remains unknown [39, 45]. 
Therefore, these data suggest that NEK11 could be regarded an interesting target 
to validate as a high-penetrance melanoma susceptibility gene. 
Genetic analysis confirmed LOH in the melanoma tissue of a mutation carrier. 
Expression of NEK11 MT and NEK11 WT allele is detected in lymphocytic RNA 
indicating that the mutant transcript is not degraded by NMD, confirmed by 
mRNA expression analysis in transfected U2OS cells. 
The oncogenicity of the NEK11 p.Arg374Ter mutation could be caused by two 
possible scenarios. First, a gain-of-function (GOF) mutation, as the non-catalytic 
C-terminal domain was shown to have an auto-inhibitory effect on protein function 
[45], thus, loss of this domain could activate the kinase activity. Alternatively, the 
mutation might lead to the synthesis of a non-functional truncated protein, e.g. 
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by loss of coiled-coil domain motifs (Supplemental Figure 3A). Here, we provide 
data strongly suggesting a LOF of the NEK11 p.Arg374Ter mutation. Collectively 
our results implicate that the truncated NEK11 protein has a very short half-
life, implying that the mutant protein is not significantly expressed in cells and 
reflects a loss-of-function. Since loss of NEK11 abrogates the G2/M cell cycle arrest 
upon DNA damaging agents and can induce apoptosis [25], it is very well possible 
that LOF results in genomic instability with the possible selection of cells with 
increased survival and proliferation, stimulating the acquirement of additional 
mutations and the development into a tumor. 
Unfortunately, our analyses of NEK11 p.Arg374Ter mutation were restricted by the 
limited availability of relevant (tumor) tissue, as we only had access to melanoma 
tissue and lymphocytic RNA from one affected family member. Analysis of tumor 
tissue from more affected family members could strengthen the case for NEK11 as 
a novel melanoma-susceptibility gene. Moreover, the NEK11 p.Arg374Ter mutation 
had 14 submissions in dbSNP, although frequency of the alternate allele was 
extremely low (0-0.00003) and was not found in the Genome of The Netherlands 
(GoNL) database [30, 46, 47]. In a recent study, >300.000 UK WES/WGS non-
melanoma data sets were analyzed for non-synonymous protein truncating 
variants (PTVs) [48], however, no mutations were identified in NEK11, further 
strengthening NEK11 to be a novel but rare melanoma-susceptibility gene and 
p.Arg374Ter as a potential pathogenic mutation.
As to why this family is predisposed to develop melanoma and not a different tumor 
type, we cannot conclude based on data from a single family. The increased risk 
of only one or a few tumor types is common in monogenic tumor predisposition 
syndromes [49]. Furthermore, the absence of any NEK11 mutation in 488 Dutch 
familial melanoma cases [50] warrants screening for NEK11 mutations in melanoma 
families worldwide in order to confirm the importance of NEK11 as a melanoma-
susceptibility gene.
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Supplemental Table 1 Sequences of primer combinations

































Supplemental Figure 1 Genotyping of a common SNP (rs4974475) in a Dutch melanoma family. 
Chromatogram showing DNA sequence and variant presence [T] in germline DNA of A) healthy 
family member 14 and in germline DNA of NEK11 p.Arg374Ter mutation carriers B) family member 7, 
C) family member 4 and D) family member 5. E) Loss of the normal allele [C] was detected in tumor DNA 
of family member 5.
Supplemental Figure 2 Relative mRNA expression data in transiently transfected U2OS cells. Relative 
mRNA levels normalized to CAPNS1 and SRPR reference genes and subsequently corrected to Tomato 
Red to correct for transfection efficiency. Data shown represent mean expression from 3 independent 
experiments. Error bars show Standard Error of the Mean (SEM). Statistical significance is shown as 
*p<0.05, **p<0.005, ***p<0.0005.
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Supplemental Figure 3 Subcellular localization of NEK11 wildtype and p.Arg374Ter proteins. A) 
Schematic representation of Flag-tagged NEK11 expression vectors, with the wildtype (WT) construct 
consisting of 645 amino acids. In purple the N-terminal catalytic domain is shown, in pink is the coiled-
coil domain and in blue the C-terminal PEST-like domain. Following site-directed mutagenesis the 
resulting NEK11 p.Arg374Ter (MT) protein consists 373 amino acids, with the whole C-terminal PEST-like 
domain and part of coiled-coil domain is lost [27] B) Immunofluorescence staining of NEK11 WT and 
NEK11 MT protein localization in U2OS cells (scale bars represent 10 μm). 
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Assessing a single SNP located 
at TERT/CLPTM1L multi-cancer 
risk region as a genetic modifier 
for risk of pancreatic cancer and 





Carriers of pathogenic variants in CDKN2A have a 70% life-time risk of developing 
melanoma and 15-20% risk of developing pancreatic cancer (PC). In the Netherlands, 
a 19-bp deletion in exon 2 of CDKN2A (p16-Leiden mutation) accounts for most 
hereditary melanoma cases. Clinical experience suggests variability in occurrence 
of melanoma and PC in p16-Leiden families. Thereby, the risk of developing cancer 
could be modified by both environmental and genetic contributors, suggesting 
that identification of genetic modifiers could improve patients’ surveillance. 
In a recent genome-wide association study (GWAS), rs36115365-C was found to 
significantly modify risk of PC and melanoma in the European population. This 
SNP is located on chr5p15.33 and has allele-specific regulatory activities on TERT 
expression. Herein, we investigated the modifying capacities of rs36115365-C on 
PC and melanoma in a cohort of 283 p16-Leiden carriers including 29 diagnosed 
with PC, 171 diagnosed with melanoma, 21 diagnosed with both PC and melanoma 
and 62 with neither PC nor melanoma. In contrast to previously reported findings, 
we did not find a significant association of PC risk with risk variant presence as 
determined by Generalized Estimating Equations (GEE) modelling. Interestingly, 
carrier-ship of the risk variant had a significant protective effect for melanoma 
(OR -0.703 [95% CI -1.201-0.205], p = 0.006); however, the observed association 
was no longer significant after exclusion of probands to assess possible influence 
of ascertainment. Collectively, genetic modifiers for the prediction of PC and 
melanoma risk in p16-Leiden carriers remain to be determined. 
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INTRODUCTION
CDKN2A is the major high-risk susceptibility gene identified thus far for familial 
melanoma [1]. In the Netherlands, the most common cause of familial melanoma 
is a CDKN2A founder mutation which is a deletion of 19bp in exon 2 (c.225_243del, 
p.(A76Cfs*64); RefSeq NM_000077.4) also known as the p16-Leiden mutation 
resulting in inactivation of tumor-suppressive properties of p16(INK4a) [2]. 
Carriers have a lifetime risk of 70% to develop melanoma [3], and a life-time risk 
of 15-20% to develop Pancreatic Cancer (PC) [4-6]. 
PC is a highly aggressive cancer subtype with very poor prognosis resulting in a 5-year 
survival rate of less than 5% [7]. It is therefore one of the leading causes of cancer-
related deaths worldwide [8] suggesting there is much to gain by early detection of PC 
at a stage when surgical removal is still curative [9]. Carriers of the p16-Leiden mutation 
are advised to undergo screening yearly for PC using MRI from the age of 45 [6]. 
Clinical studies of p16-Leiden mutated families have shown variability in occurrence 
of melanoma and PC among families suggesting contribution of modifying factors 
to cancer risk [4]. For example, genetic risk factors such as MC1R, were found to 
modify risk of developing melanoma in p16-Leiden positive families significantly 
[10, 11]. Therefore, the variable occurrence of PC in those families might also be 
explained by modifying genetic risk factors other than the p16-Leiden mutation. 
Determination of those factors would allow for a better identification of patients 
at increased risk that might benefit from personalized clinical management.
In an attempt to identify genetic factors that modulate the risk of pancreatic cancer 
in p16-Leiden carriers, Potjer et al., analyzed seven SNPs associated with PC risk in the 
general population in this cohort of carriers and found no significant association [12]. 
Recently a risk variant, rs36115365-C, was identified to be significantly correlated with 
PC risk in the European population [13]. This SNP is located at a multi-cancer risk 
locus on chr5p15.33 and was found to have allele-specific regulatory activities on TERT 
expression, mutations of which have been associated with melanoma risk [14]. These data 
suggest that variation within rs36115365 (G,C) could contribute to cancer development. 
Indeed, carriers of the minor C-allele are at increased risk of pancreatic cancer (RR=1.2). 
Remarkably at the same time, carriers of this C-allele are at diminished risk of developing 
melanoma [13]. Several risk variants have been reported to be associated with a small but 
important protective effect against melanoma in sporadic melanoma such as variants 
in GSTM1 and GSTT1 [15] and polymorphisms in the Vitamin D receptor gene [16]. These 
findings collectively suggest that identification of genetic modifiers in p16-Leiden carriers 
could be used to estimate the risk of developing PC and melanoma more accurately. This 
study therefore investigates and verifies the risk impact of the reported SNP variant, 




The study population included only confirmed p16-Leiden carriers of which DNA 
samples were available from the Laboratory for Diagnostic Genome Analysis 
(LDGA) of Leiden University Medical Center (LUMC). Subject-specific clinical 
information was collected between 1998 and the 1st of January, 2015. Cases of 
PC were individuals carrying the p16-Leiden mutation who were diagnosed with 
primary exocrine PC. Similarly, cases of melanoma were p16-Leiden carriers who 
were diagnosed with cutaneous (multiple) melanoma. Detailed medical record 
data on the study population has been reported previously [12]. Approval of this 
study was obtained from the ethics committee of Leiden University Medical Center 
(LUMC #P14.148) [12]. 
In total, 419 p16-Leiden carriers were available for inclusion in the current study. The 
comparative analysis was formulated by filtering for carriers diagnosed with PC, 
carriers diagnosed with melanoma, and a group who did neither develop PC nor 
melanoma but were older than 55 years of age. Subsequently, a master cohort of 
283 p16-Leiden carriers from a total of 121 p16-Leiden families were included. These 
consisted of 29 carriers with PC (median age 47 years), 171 with melanoma (median 
age 60), 21 with both PC and melanoma (median age 60) and 62 with neither PC nor 
melanoma (median age 71) (Table 1). 
Genotyping and statistical analysis
Genotyping analysis was carried out using the rhAmp-SNP Genotyping Assay 
(Integrated DNA Technologies (IDT), Leuven, Belgium). Bi-allelic discrimination 
was achieved by incorporation of two forward primers specifically targeting 
the allele of interest (rs36115365-C). The genotyping procedure was performed 
according to manufacturer’s instructions. The reference allele was labelled with 
FAM reporter dye and the alternate allele with Yakima Yellow (YY) reporter dye 
which were both detected on CFX384 Touch Real-Time PCR Detection System (Bio-
Rad, Veenendaal, The Netherlands) with excitation sources and emission filters for 
respective wavelengths. The minor allele frequency (MAF) was calculated based on 
Hardy-Weinberg law. For statistical analysis, a generalized linear model with logit 
link was used to assess the association between alternate-allele presence and risk 
for PC and melanoma development. The binary dependent variable was either PC 
or melanoma and SNP variant was the explanatory indicator variable. Regression 
coefficients and 95% Confidence Intervals (CI) were calculated. P-values of <0.05 
were considered statistically significant.
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Due to nature of this family-based study, individuals are not independent, they are 
clustered. In order to account for this feature, a Generalized Estimating Equations 
(GEE) procedure was used to fit the model. The GEE procedure allows to deal with 
clustered data. Since the specific correlation structure of this data is difficult 
to estimate due to the small sample size, an independence working correlation 
structure was assumed. To avoid the impact of possible misspecification of the 
model in the confidence intervals and p-values, robust estimates of the standard 
errors were obtained using a sandwich estimator [17]. All statistical analyses were 
performed using IBM SPSS Statistics 23.
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RESULTS
The risk impact of rs36115365-C on PC was calculated by comparing a total of 50 
p16-Leiden carriers who developed PC (median age 50) to 143 controls (median age 
74) consisting of 62 carriers who did not develop PC and 81 carriers who developed 
melanoma but were older than 55 years of age (sub-cohort characteristics, Table 2). 
Similarly, the risk impact of rs36115365-C on melanoma was calculated by comparing 
a total of 192 p16-Leiden carriers who developed melanoma (median age 60) to 73 
controls (median age 71) consisting of 62 carriers who did not develop melanoma 
and 11 carriers who developed PC but were older than 55 years of age (sub-cohort 
characteristics, Table 3). The latter group in both analyses was treated as a control 
since it consisted of p16-Leiden carriers older than 55 years of age with a subsequent 
reduced risk of developing melanoma or pancreatic carcinoma in the future. 
MAF of the risk variant rs36115365-C for different comparison groups, Beta values 
and 95% CI were calculated (Table 4). No significant association was found for 
risk variant presence and PC risk (Table 4). Interestingly, a significant negative 
association was observed for risk variant carriers and melanoma development 
suggesting a protective effect of rs36115365-C for melanoma in p16-Leiden carriers 
(OR=-0.703, 95% CI (-1.201,-0.205), p-value=0.006) (Table 4). To assess possible 
influence of ascertainment in the sample cohort, the association with melanoma 
was further explored by excluding probands. This resulted in a decreased cohort 
size of 69 families consisting of 158 p16-Leiden carriers, 85 of whom had developed 
melanoma. The statistical significant association did not remain in that case for 
risk variant carriers (GEE model -0.453,95% CI (-1.051,0.145), p-value = 0.138).
63
3Chapter 3 | Assessing a single SN
P located at TERT/CLPTM
1L m
ulti-cancer risk region 












Median age (yrs) 47 (21-72) 60 (27-93) 60 (42-78) 71 (55-86)
Gender (M:F) 9:20 71:100 8:13 26:36
Multiple melanoma - 71/171 (42%) 6/21 (29%) -
Patients diagnosed 
with other cancer
3 33 6 24
* p16-Leiden carriers who developed either pancreatic cancer or melanoma or neither of the two and were 
older than 55 years of age served as controls in comparative analysis, see tables 2 and 3
Table 2 Sub-cohort characteristics of p16-Leiden carriers with/without pancreatic cancer
Pancreatic cancer cases 
(N=50)
Non-Pancreatic cancer controls 
(N=143)
Median age (yrs) 50 (21-78) 74 (55-93)
Gender (M/F) 17/33 60/83
Medical history of melanoma 21 81
Multiple melanoma 6/21 (29%) 37/81 (46%)
Patients diagnosed with other cancer 9 51
Table 3 Sub-cohort characteristics of p16-Leiden carriers with/without melanoma
Melanoma cases  
(N=192)
Without melanoma controls 
(N=73)
Median age (yrs) 60 (27-93) 71 (55-86)
Gender (M/F) 79/113 28/45
Medical history of pancreatic cancer 21 11
Multiple melanoma 77/192 (40%) -
Patients diagnosed with other cancer 54 24
Table 4 Association of rs36115365-C presence with PC and melanoma in p16 –Leiden carriers
Condition MAF 
rs36115365 (G,C)
Allelic OR 95% CI p-value
Cases Controls 
Pancreatic cancer 0.23 0.23 -0.027 -0.804 0.750 0.946
Melanoma 0.21 0.29 -0.703 -1.201 -0.205 0.006
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DISCUSSION 
Identification of genetic modifiers for PC and melanoma risk in p16-Leiden carriers 
could possibly explain the variability of cancer occurrence within p16-Leiden positive 
families and ultimately favor individualized surveillance and clinical management 
of those patients [4, 12]. Herein, we sought to estimate the risk of developing PC 
and melanoma more accurately in carriers of the pathogenic variant p16-Leiden. 
This was tested by determining whether a previously published associated risk 
variant for PC and melanoma, rs36115365-C [13], could explain modified risk in a 
homogeneous population of p16-Leiden carriers.
The MAF of rs36115365-C in the general European (Non-Finnish) population is 0.18 
[18] and in the Netherlands specifically, it is 0.20 [19] indicating a common variant 
with high chances of detection. In this case, the second most-common allele (C) 
was detected with MAFs ranging from 0.21-0.29 in 283 p16-Leiden carriers, slightly 
higher than in the general population. A limitation of this study however is the 
small cohort size that could limit possibilities of detecting statistical associations. 
Moreover, selecting subjects older than 55 years of age not only reduced the control 
group size but also the possibility of developing PC or melanoma in the future was 
not fully excluded. A GEE statistical procedure was applied as it is appropriated for 
studying family-based associations [17, 20]. There was no significant association 
between rs36115365-C presence and PC-risk in p16-Leiden carriers.
Several efforts in scientific literature focused on identifying genetic modifiers of PC 
risk in CDKN2A-mutation carriers. Yang et al., applied Whole Exome Sequencing 
(WES) in 66 PC patients with/without CDKN2A mutation. The combined data 
from five research groups, including 13 pancreatic CDKN2A mutated (p16-Leiden) 
cases from the Netherlands identified 35 variants in PC-related genes. Nominally 
significant associations were obtained for mismatch repair genes (MLH1, MSH2, 
MSH6, PMS2) in all PC patients, however, variants in ATM, CPA1, and PMS2 were only 
observed in CDKN2A wild-type PC patients. Further, nine CDKN2A mutated and four 
CDKN2A wild-type PC patients had rare potentially deleterious variants in multiple 
PC-related genes. These results therefore suggest that a subset of PC patients may 
have increased risk because of germline mutations in multiple PC-related genes [21]. 
Nonetheless, p16-Leiden carriers described in the study by Yang were not included 
in the current study. In addition, the same group showed that sequencing analysis 
of PALB2, another high susceptibility gene for PC, did not reveal any deleterious 
mutations in PC patients from CDKN2A mutated families [22]. Potjer et al., who 
studied the same cohort of p16-Leiden carriers, as in the current study did not identify 
an association of seven PC-related SNPs with PC risk [12]. Therefore, consideration 
of other genetic modifiers yet unknown could be an additional explanation of the 
variability in occurrence of PC within p16-Leiden families.
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Moreover, epidemiological studies suggest that non-genetic factors may also 
contribute to PC development specifically in p16-Leiden carriers, with the most 
significant one being smoking [23] as well as alcohol use and obesity in the general 
population [24]. Collectively these data suggest that rs36115365-C risk variant 
could not be used to estimate the risk of PC in p16-Leiden mutation carriers more 
accurately unlike in the European population published previously [13]. 
Modifier genes for melanoma have been well described in literature for CDKN2A 
mutation carriers [10, 11, 25, 26]. The variant rs36115365-C, previously published 
to be negatively correlated with melanoma risk [13] had a significantly negative 
association with melanoma development in this study. This effect did not remain 
however when excluding probands from the analysis suggesting that ascertainment 
of melanoma cases influenced the results. 
CONCLUSION 
Here, no significant association was found between rs36115365-C presence and risk 
of PC development in p16-Leiden carriers in contrast to previous published literature 
in the European population. Reversely, a statistically significant protective effect 
was determined for melanoma risk in the same cohort of p16-Leiden carriers, an 
effect that lost significance when excluding melanoma probands. Collectively, 
genotyping and statistical data suggest that genetic modifiers for the prediction 
of PC and melanoma in p16-Leiden carriers remain to be determined.
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Loss of wild-type CDKN2A  
is an early event in the 





The development of melanoma involves a sequence of genetic and epigenetic 
alterations. CDKN2A is a key tumor suppressor gene that is commonly inactivated 
in invasive melanoma, but not in benign precursor lesions. Heterozygous germline 
mutations in CDKN2A cause hereditary melanoma, also termed Familial Atypical 
Multiple Mole Melanoma (FAMMM) syndrome. The objective of this study was 
to investigate CDKN2A loss-of-heterozygosity (LOH) in melanocytic neoplasms 
of FAMMM syndrome patients. Here we applied digital PCR methodology for 
absolute quantification of allelic imbalance of SNPs at the CDKN2A locus. Allelic 
imbalance consistent with CDKN2A LOH was observed in 9/14 (64%) primary 
melanomas. Remarkably, CDKN2A LOH was present in 7/13 (54%) common 
melanocytic nevi with no histopathological atypia. Digital PCR provided insight 
into tumor heterogeneity and the order of genetic events by quantification of 
CDKN2A LOH relative to BRAFV600E, TERT promoter mutation and chromosome 9q 
loss. In nevi, a subclonal fraction of cells demonstrated CDKN2A LOH and this 
genetic event occurred subsequent to BRAF mutation. TERT promoter mutation 
and loss at chromosome 9q were observed later in melanoma development of 
FAMMM syndrome patients. In FAMMM syndrome patients CDKN2A inactivation 
can occur at an earlier stage of genomic evolution of melanocytic neoplasia.
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Approximately 10% of patients diagnosed with melanoma report a positive 
family history of this aggressive cutaneous malignancy. Familial or hereditary 
melanoma is arbitrarily defined as the occurrence of three or more cases of 
melanoma within a family [1]. At least a third of melanoma families are caused by 
germline heterozygous mutations of the CDKN2A gene [2]. Hereditary melanoma 
due to germline CDKN2A mutation is designated familial atypical multiple mole 
melanoma syndrome (FAMMM syndrome) [3]. CDKN2A-mutation carriers have an 
estimated 70% lifetime risk of developing melanoma and are at increased risk for 
pancreatic cancer, head and neck cancer as well as other tumor types [4, 5]. This 
dominant high penetrance melanoma susceptibility gene, encodes for two tumor 
suppressor proteins that are translated in alternate reading frames from the alpha 
and beta transcript [6]. The larger α transcript encodes for p16INK4A, a protein 
that mediates G1 arrest by inhibiting the phosphorylation of Cyclin-D1-CDK4/6 
complex [7, 8]. The smaller β transcript encodes for p14ARF which inhibits MDM2, 
thereby promoting p53 activity [9, 10].
In carriers of germline CDKN2A mutations, the wild-type allele is functionally 
inactivated in melanoma by a second somatic event, commonly through deletion 
[11]. The importance of CDKN2A as a tumor suppressor gene is underscored by 
the high frequency of somatic mutation, chromosomal deletion and promoter 
hypermethylation, estimated at 40%, in sporadic melanoma [12, 13]. In the 
Netherlands, a specific founder mutation, a 19-bp deletion in exon 2 of the 
CDKN2A gene (c.225_243del, p.(A76Cfs*64)) known as the p16-Leiden mutation, is 
the most frequent cause of hereditary melanoma [14]. Loss of p16 INK4A function, 
that occurs in hereditary as well as sporadic melanoma, not only disrupts the G1 
cell cycle checkpoint, but also promotes invasive behavior of melanoma cells due to 
deregulation of the BRN2 transcription factor [15]. 
The most frequent de-regulated pathway in melanocytic transformation is 
the mitogen-activated protein kinase (MAPK) pathway [16]. The two most 
common mutated genes are BRAF and NRAS occurring in a mutually exclusive 
pattern. In melanomas of germline CDKN2A mutation carriers BRAF and NRAS 
mutations were reported in 43% and 11% respectively [17]. In addition, the genetic 
landscape of sporadic melanomas frequently involves upregulation of telomerase 
reverse transcriptase (TERT) expression through promoter mutation in primary 
melanoma [16]. TERT promoter mutations create ETS/TCF transcription factor 
binding motifs that increase TERT gene expression. These mutations can be 
found in both BRAF and NRAS mutant cases with the majority occurring at two 
hotspots [18, 19]. In sporadic melanoma, somatic mutations typically sequentially 
induce MAPK pathway activation (BRAF, NRAS), upregulation of telomerase 
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(TERT) and disruption of the G1/S cell cycle checkpoint (CDKN2A) in addition to 
many other pathogenic alterations [16]. Bi-allelic loss of the CDKN2A  locus is the 
most common genetic alteration  distinguishing melanocytic nevi from invasive 
melanomas [19]. CDKN2A LOH has been previously demonstrated in primary 
and metastatic melanomas of FAMMM syndrome patients [20, 21]. The timing of 
wild-type CDKN2A inactivation in the development and progression of hereditary 
melanoma due to germline CDKN2A mutation remains to be resolved.
To evaluate the occurrence and timing of somatic events in melanoma-genesis 
for FAMMM syndrome patients, we developed an innovative digital PCR (dPCR) 
method allowing accurate quantification of somatic wild-type CDKN2A allele 
loss in patients’ tumors including melanomas and common melanocytic nevi. 
Moreover, dPCR was used to quantify presence of BRAFV600E mutation and the two 
most frequent TERT promoter mutations. 
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This study was performed on a cohort of 20 heterozygous and one homozygous 
carrier of a germline inactivating CDKN2A mutation (p16-Leiden). Blood DNA from 
CDKN2A mutation carriers was available for analysis. Tumor DNA was derived from 
18 melanoma and 17 common melanocytic nevi (not matched from the same lesion) 
formalin-fixed paraffin-embedded (FFPE) tissue samples from CDKN2A mutation 
carriers and extracted by macrodissection with the QIAamp DNA Micro Kit (Qiagen) 
or with the Maxwell 16 FFPE Plus LEV DNA Purification kit (Promega, Leiden, The 
Netherlands). Due to quality control measurements, the analysis was restricted to 14 
melanoma and 13 common melanocytic nevi. The pathological diagnosis of all lesions 
was made by two melanoma pathologists independently. The common melanocytic 
nevi did not show morphologically distinct nevus cell subsets.
Digital PCR (dPCR) analysis
A digital PCR assay was designed targeting a common tri-nucleotide single 
nucleotide polymorphism (SNP) within the intronic region of CDKN2A, rs2811708, 
located 2kb upstream the 19-bp deletion (p16-Leiden mutation) site (G/A/T, 
chr9:21973422, rs2811708-[T] AF in the Dutch population is 26%, [19]) (Table 1). To 
validate the assay performance and confirm the copy number amplification within 
CDKN2A region, a different intronic SNP, rs3731257, located 4kb downstream the 
p16-Leiden mutation site was amplified by dPCR (G/A, chr9:21966221, rs3731257-A, 
AF in the Dutch population is 26% [19]) (Table 1, Figure 1). To control for allelic 
imbalance and loss in 9p21, the 9q region was targeted by amplifying a SNP, 
rs4745670, located within GNAQ intronic region (T/A, chr9:80423139, rs4745670-
[A] AF in the Dutch population is 70% [19]) (Table 1). This SNP-based digital PCR 
approach follows the design guidelines of a mutation specific digital PCR reaction 
as described previously [52]. 
Sanger Sequencing analysis long-run (BaseClear, Leiden, The Netherlands) 
(Table 1) was performed to validate primer-combinations of the different SNP-
assays and chromatograms were analyzed using Chromas software (Technelysium, 
South Brisbane, Australia). The two most frequent TERT promoter mutations 
(c.1-146C>T and c.1-124C>T) and the BRAFV600E mutation were examined using 
mutation detection dPCR assays predesigned by Bio-Rad (Hercules, California, 
United States). Raw digital PCR results were acquired using QuantaSoft (version 
1.7.4, Bio-Rad Laboratories) and imported in an online digital PCR management 
and analysis application Roodcom WebAnalysis (version 1.9.4, available via 
https://webanalysis.roodcom.nl). The fractional abundance (%) of the alteration 
of interest (CDKN2A LOH, TERT promoter, 9q LOH and BRAFV600E) was calculated 
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by dividing the mutant allele counts over the total allele counts. The mutant allele 
fraction was determined and multiplied by two to obtain the mutant cell fraction:
 
Allelic SNP imbalance was analyzed using in-house developed digital PCR assays 
(Table 1). Assuming the allele linked to the p16-Leiden deletion remains stable, the 
copy number value (average number of total CDKN2A alleles per cell) was calculated 
as follows:
 
A copy number significantly lower than 2 was interpreted as being the sum of 
normal cells (CNV=2) and cells with LOH (CNV=1). The presence of LOH was 
therefore determined as follows:
For the 9q SNP (rs4745670), the variant with the highest concentration was assumed 
to be stable and the fraction of cells with LOH was determined as above.
Table 1 Primer/Probe combinations used for digital PCR and sanger sequencing analyses
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A Single Nucleotide Polymorphism (SNP)-based digital PCR 
approach to detect allelic imbalance in FAMMM syndrome patients
Detection of a 19 bp-deletion (p16-Leiden mutation) in degraded DNA derived 
from formalin-fixed paraffin embedded (FFPE) tissue samples turned out to be 
troublesome, also due to the size difference between wild-type and mutant CDKN2A 
target that caused an amplification bias (Supplemental Figure 1). Therefore, an 
approach was developed for accurate copy number determination through SNP-
specific dPCR technology [22]. The SNP rs2811708 located in intron 1 of the CDKN2A 
gene and 2kb upstream of the p16-Leiden mutation had a MAF of 26% in the Dutch 
population (Figure 1A) [23]. A SNP located 4kb downstream the p16-Leiden mutation, 
rs3731257, was included to confirm the presence of allelic imbalance within 9p21 and 
had a MAF in the Dutch population of 26%, (Figure 1A) [23]. To investigate the presence 
of deletions across chromosome 9 or gross genomic instability in melanomas, a SNP 
at chromosome 9q (rs4745670) located in an intron of the GNAQ gene was included 
with MAF in the Dutch population of 70% (Figure 1A) [23].
To distinguish the different genotypes of common SNPs located within the 9p21 locus 
(rs2811708 and rs3731257) and rs4745670 located at 9q, capillary sequencing analysis 
was performed on blood DNA of p16-Leiden mutation carriers (Figure 1B). The minor 
variant allele rs2811708-[T], was found to be linked to this pathogenic germline 
variant (Figure 1C). This was concluded from analyzing all available p16-Leiden carriers 
and specifically from homozygous carriers of the p16-Leiden allele who were also 
homozygous for rs2811708-[T] (Figure 1B and C). For the confirmative SNP, rs3731257-
[C] was present in all p16-Leiden carriers and homozygous carriers of the p16-Leiden 
allele were also homozygous for rs3731257-[C] (Figure 1B). This shows that the normal 
allele [C] was linked to the p16-Leiden mutation (Figure 1C). 
Since we confirmed linkage of the different SNPs to the p16-Leiden mutation and 
included a common SNP on the 9q arm as a control, this SNP-based digital PCR 
approach allowed for quantification of CDKN2A allelic imbalance and loss in 
tissues of FAMMM syndrome patients. 
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Loss-of-heterozygosity (LOH) of the CDKN2A locus in melanomas 
from FAMMM syndrome patients 
After having confirmed the specificity of our digital PCR assays, we analyzed 
melanoma lesions from CDKN2A mutation carriers to study allelic imbalance (Figure 
2A, Supplemental table 1). The pathological diagnosis of all lesions was made by two 
melanoma pathologists independently. Absolute quantification showed that in blood 
DNA of a CDKN2A mutation carrier there was 50% fractional abundance of an upstream 
SNP adjacent to the CDKN2A locus (rs2811708) consistent with heterozygosity (Figure 
2A). Loss of wild-type CDKN2A allele was detected in 9/14 (64%) melanomas of 
FAMMM syndrome patients by the upstream SNP (rs2811708) (Figure 2). Additional 
mutation analysis in melanomas showed that 7/14 (50%) tested positive for a BRAFV600E 
Figure 1 SNP-specific dPCR analysis schematic A) Schematic of the genomic location used to design the 
digital PCR (dPCR) assays amplifying three common SNPs within chromosome 9: one located in intron 1 of 
CDKN2A, 2kb upstream the p16-Leiden mutation (rs2811708) and a second SNP located within the intronic 
region of 9p21 (rs3731257) at 4kb downstream the p16-Leiden mutation. A third SNP was located within the 
intronic region of 9q (rs4745670) and was used as a control. B) Example of genotype from a heterozygous 
individual for rs2811708 [G/T], rs3731257 [C/T] and rs4745670 [T/A] and a homozygous p16-Leiden carrier who 
was also homozygous for rs2811708-[T], rs3731257-[C] and rs4745670-[A]. C) Schematic of linkage between 
rs3731257-[C] and rs2811708-[T] allele to the p16-Leiden mutation (WT- wild-type, MT-mutant).
77
4Chapter 4 | Loss of w
ild-type CD
KN








mutation and 6/14 (43%) tested positive for a TERT promoter mutation (Figure 2B). 
Allelic imbalance within 9p21 locus was validated by the fractional abundance of the 
downstream SNP (rs3731257) in informative (heterozygous for SNP) cases (Figure 3A). 
These data show wild-type CDKN2A LOH as a common event in patients with familial 
melanoma, leading to the bi-allelic inactivation of CDKN2A.
In order to investigate loss at chromosome 9, we quantified a common SNP on the 9q 
arm (rs4745670). We found that 5/14 (36%) of melanoma had a significant imbalance 
in amplification (Supplemental figure 2A, Figure 2B) indicating additional deletions 
across chromosome 9, an event that has been reported previously in sporadic and 
familial melanomas [24]. Since we found wild-type CDKN2A loss to be an early 
event, in a similar proportion of cells as the BRAFV600E mutation, we investigated the 
frequency of CDKN2A allelic imbalance in common melanocytic nevi. 
Figure 2 Absolute quantification of genetic events in melanoma lesions from FAMMM syndrome 
patients. A) Absolute quantification of rs2811708-[T] fractional abundance in blood DNA and primary 
melanoma lesions from p16-Leiden mutation carriers. Error bars represent the 95% confidence intervals 
(CIs) based on Poisson statistics B) Summary of CDKN2A loss-of-heterozygosity (LOH) (rs2811708), BRAFV600E 
mutation, 9q LOH (rs4745670) and pTERT mutation (c.1-146C>T or c.1-124C>T) in melanomas of FAMMM 
syndrome patients (n=14). Color legend = positive (mutant or LOH confirmed), white = negative (wild-type 
or no LOH), grey = not available (not informative, low DNA, low number of droplets or not analyzed).
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CDKN2A LOH in common melanocytic nevi from FAMMM syndrome 
patients
Given the high absolute abundance of loss of wild-type CDKN2A in melanomas, 
we analyzed allelic imbalance in common melanocytic nevi from FAMMM 
syndrome patients (Supplemental table 1). It is well established that the CDKN2A 
locus remains intact in nevi, whereas homozygous deletion is a common event 
in sporadic melanomas and is the main cause of inactivation of this tumor 
suppressor gene [19]. We chose to analyze common, benign nevi without clinical 
or histopathological atypia, because dysplastic nevi as intermediate lesions can be 
difficult to distinguish from early stage melanoma.
CDKN2A LOH has been previously shown at primary melanoma and metastasis stage 
of FAMMM syndrome patients [20, 21]. Remarkably, in this study loss of the wild-type 
CDKN2A allele was detected in 7/13 (54%) common melanocytic nevi from FAMMM 
Figure 3 Validation of allelic imbalance within 9p21 locus in melanomas and common melanocytic 
nevi. Absolute quantification of rs2811708-[T] and rs3731257-[C] fractional abundance in blood DNA and 
A) Primary melanoma lesions B) Common melanocytic nevi
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syndrome patients, based on absolute quantification of rs2811708 allelic imbalance 
(Figure 4A). In addition, 8/13 (62%) common nevi tested positive for BRAFV600E mutation 
and five BRAF mutant nevi showed significant CDKN2A LOH (Figure 4B). As for the 
melanoma samples, in all informative nevus samples, allelic imbalance of rs3731257 
located downstream of CDKN2A confirmed loss of the entire CDKN2A locus (Figure 
3B). We did not detect allelic imbalance at 9q (GNAQ locus) in any of the nine tested nevi 
(Supplemental figure 2B, Figure 4B). The identification of subclonal CDKN2A allelic 
imbalance in common melanocytic nevi instigated histopathological re-evaluation 
of the lesions which confirmed absence of cytonuclear or tissue architectural atypia 
(Supplemental figure 3). The clinical and pathological characteristics do not distinguish 
nevi with CDKN2A LOH and nevi without LOH (Supplemental Table 2). Collectively, 
these data demonstrate bi-allelic loss of CDKN2A already at the common melanocytic 
nevus stage in CDKN2A mutation carriers. 
Figure 4 Absolute quantification of genetic events in common melanocytic nevi from FAMMM syndrome 
patients. A) Absolute quantification of rs2811708-[T] fractional abundance in blood DNA and common 
melanocytic nevi from p16-Leiden mutation carriers. Error bars represent the 95% CIs based on Poisson 
statistics B) Summary of CDKN2A LOH (rs2811708), BRAFV600E mutation and 9q LOH (rs4745670) in common 
melanocytic nevi from FAMMM syndrome patients (n=13). Color legend = positive (mutant or LOH confirmed), 
white = negative (wild-type or no LOH), grey = not available (low DNA, low number of droplets, not analyzed).
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Genetic events in nevi and melanomas of FAMMM syndrome patients
Based on combined absolute quantification of mutations and losses, we attempted 
to deduce the order of genetic events in melanoma and common melanocytic nevi 
from patients with FAMMM syndrome. In BRAF mutant melanocytic nevi, CDKN2A 
LOH was detected in a significantly smaller proportion of the cells than the BRAFV600E 
mutation (Figure 5A, Supplemental Table 1). This suggests that BRAF mutation 
occurs prior to CDKN2A LOH. We found no deletions at chromosome 9q in the nevi. 
The BRAF mutant melanoma biopsy samples contained between 21% and 87% of cells 
harboring a BRAFV600E mutation, due to different proportions of admixed resident 
and infiltrating cells. Copy number alterations for BRAF and TERT were observed 
in a single melanoma lesion that was positive for CDKN2A LOH (Supplementary 
Table 1). The cell fraction harboring BRAFV600E mutation, CDKN2A LOH and TERT 
mutation was similar in all investigated samples, precluding determination of 
the order of these ubiquitous genetic events (Figure 5B, Supplemental Table 1). In 
five melanoma samples, allelic imbalance at 9q (rs4745670) was found; in one case 
(1023), the fractional abundance of this SNP was significantly lower than that of 
the CDKN2A SNPs (Figure 5B), showing that loss of chromosome 9q occurs in a 
subclone of cells that already were affected by loss of wild-type CDKN2A.
Figure 5 Summary of genetic events in common melanocytic nevi and primary melanomas. All values 
represent estimates on the fraction of cells having a certain alteration, relative to the complete sample (all 
cells). This is either a mutation of BRAFV600E and pTERT (c.1-146C>T or c.1-124C>T) or loss-of-heterozygosity 
(LOH) for CDKN2A (rs2811708) and 9q (rs4745670) A) In common melanocytic nevus samples 1065 and 1071 
B) In primary melanoma samples 1001 and 1023. Error bars represent 95% CIs based on Poisson statistics. 
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The genetic evolution of melanoma is characterized by key oncogenic drivers 
mainly involving the BRAF, NRAS, TERT, CDKN2A and PTEN genes [15]. Bi-allelic 
inactivation of CDKN2A is a common event in sporadic melanomas, with deletion 
being the main genetic mechanism [19]. Studies in primary human melanocytes 
have also revealed that engineering of CDKN2A deletions confer migratory and 
invasive phenotypes [15]. Homozygous deletion of CDKN2A has been reported in 
a small proportion of sporadic dysplastic nevi but never in common melanocytic 
nevi [15, 25]. In familial melanoma, CDKN2A LOH has been previously reported in 
primary and metastatic lesions of germline CDKN2A mutation carriers [20, 21].
Digital PCR assays targeting SNPs in close proximity to the p16-Leiden mutation 
site were developed to provide precise quantification of allelic imbalance in 
melanoma and common melanocytic nevus FFPE tissue samples to study LOH of 
the CDKN2A gene. In all informative cases, the fractional abundance of the SNP, 
located downstream of CDKN2A, confirmed the allelic imbalance detected using 
the SNP located upstream this locus. 
Loss of the CDKN2A wild-type allele was observed in 9 of 14 (64%) melanomas in 
FAMMM syndrome. Bi-allelic CDKN2A inactivation may be more prevalent, as 
intragenic mutation and promoter hypermethylation may result in functional 
inactivation in addition to LOH that was investigated here. The dPCR method 
optimized for this study is specifically able to detect gene variants at a single locus, 
allowing quantification of allelic imbalances and hotspot mutations. It is not 
suited to simultaneously quantify various mutations distributed over a gene such 
as PTEN. Moreover, our analyses are restricted by small amounts of available DNA 
from the dissected melanocytic lesions. For many samples we have insufficient 
DNA to perform new analysis on a gene, in addition to CDKN2A, BRAF and TERT.
Remarkably, CDKN2A LOH was detected in 7 of 13 (54%) common melanocytic nevi 
of FAMMM syndrome patients. In melanoma, allelic imbalance at the CDKN2A locus 
occurred in all cells carrying a BRAFV600E mutation. By contrast, in common nevi, 
loss of the wild-type CDKN2A allele occurred in a subclone of cells that had acquired 
BRAFV600E mutation at an earlier stage of its development. Subclonal loss of the wild-
type CDKN2A allele in melanocytic nevi was not associated with histopathological 
alterations; the lesions showed no tissue architectural or cytonuclear atypia. It is 
plausible that nevi containing subclones with bi-allelic inactivation of CDKN2A 
might be at higher risk to develop into melanoma. TERT promoter mutations could 
be detected in a subset of melanoma samples of FAMMM syndrome patients, but 
were not found in the few melanocytic nevi that were investigated.
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In a proportion of melanocytic nevi of patients with BAP1 tumor predisposition 
syndrome, immunohistochemical analysis shows loss of BAP1 expression, commonly 
in a regional part of the lesion [26]. These BAP1-deficient melanocytic nevi, also 
termed melanocytic BAP1-associated intradermal tumors (MBAITs) or BAP-omas 
usually show clinical and histopathological atypia [26]. Due to the fact that p16INK4A 
is not uniformly expressed in nevi and truncated p16INK4A protein encoded by mutant 
CDKN2A is recognized by most antibodies, at the same level as p16INK4A wild-type 
protein, confirmation of p16INK4A -loss was not possible at the protein level. 
This study presents for the first time, CDKN2A LOH as an early event in melanoma 
evolution of FAMMM syndrome patients, relative to other driver events (BRAF, 
TERT). Our quantitative data suggest that chromosome 9 disruption in hereditary 
melanoma consists of two steps; firstly by focal deletion of the CDKN2A locus and 
secondly by a deletion of chromosome 9 in melanomas. In conclusion, the absolute 
quantification of allelic imbalance using digital PCR has wider applications in 
determining the genomic evolution of melanoma and other tumor types. In contrast 
to sporadic melanoma, CDKN2A LOH may occur in a subclone of melanocytes that 
have acquired a mutation in BRAF during nevogenesis. We speculate that subclones 
of nevus cells with CDKN2A LOH are prone to progress to melanoma. 
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Supplemental Table 1 Summary of estimates on the fraction of cells having a certain alteration, relative 
to the complete sample (all cells). These include BRAFV600E mutation, CDKN2A LOH (rs2811708), CDKN2A 
LOH (rs3731257), 9q LOH (rs4745670) and pTERT mutation (c.1-146C>T or c.1-124C>T). Benign nevi (n=13) 
and primary melanomas (n=14) (wild-type- WT, not significant- n/s, Not informative or homozygous for 
SNP- n/i, Not reliably measurable i.e <=5 droplets positive- n/m, copy number amplification- CNA).
Group Clinical no BRAF V600E rs2811 rs3731 rs4745 TERT C250T TERT C228T
SCAR 4049 WT n/s n/i n/s n/a n/a
SCAR 3749 WT n/s n/i n/i n/a n/a
BENIGN NEVUS 1063 28% n/s n/i n/s WT n/a
BENIGN NEVUS 1065 38% 7% 16% n/s n/a n/a
BENIGN NEVUS 1072 44% 20% n/i n/s WT n/a
BENIGN NEVUS 1061 47% 18% n/i n/s n/a n/a
BENIGN NEVUS 1071 60% 32% 31% n/s WT n/a
BENIGN NEVUS 10542 12% n/s n/i n/i n/a n/a
BENIGN NEVUS 1067 42% 29% 37% n/s WT n/a
BENIGN NEVUS 1068 n/m n/s n/s n/m n/a n/a
BENIGN NEVUS 1058 n/m n/s n/i n/m WT n/a
BENIGN NEVUS 1060 n/m n/s n/m n/m n/a n/a
BENIGN NEVUS 1066 n/m 51% n/i n/s n/a n/a
BENIGN NEVUS 1064 n/m 46% n/i n/i n/a n/a
BENIGN NEVUS 5412 9% n/s n/i n/s n/a n/a
MELANOMA 1002 120% (CNA) 80% n/i 72% 156% (CNA) n/a
MELANOMA 1004 21% 20% n/i n/i 28% WT
MELANOMA 1001 30% 33% 51% 35% n/m 26%
MELANOMA 1012 31% 35% n/i n/s WT 34%
MELANOMA 1005 36% 9% 7% 12% WT n/a
MELANOMA 1019 36% 42% n/i n/i n/m 26%
MELANOMA 1016 87% 71% n/i 55% WT n/m
MELANOMA 1007 n/m n/s n/m n/m n/m n/m
MELANOMA 1017 WT n/s n/i n/i n/a WT
MELANOMA 1006 WT n/s n/m n/s n/m n/m
MELANOMA 1000 WT n/s n/m n/s n/m n/m
MELANOMA 1010 WT n/s n/m n/i n/m n/m
MELANOMA 1023 WT 73% 71% 46% WT 63%
MELANOMA 1062 WT 14% n/i n/i n/a n/a
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BN 1063 50 female 6mm lower back dermal nevus.
No dysplasia.
BN 1065 38 male 7mm abdomen compound nevus.
No dysplasia.
BN 1072 47 male 7mm back junction nevus.
No dysplasia.
BN 1061 35 female 6mm scalp dermal nevus.
No dysplasia.
BN 1071 47 female 7mm abdomen compound nevus.
No dysplasia.
BN 10542 54 male 6mm lower back compound nevus.
No dysplasia.
BN 1067 37 female 7mm flank junction nevus.
No dysplasia.
BN 1068 43 male 8mm scalp dermal nevus.
No dysplasia.
BN 1058 54 male 6mm back compound nevus.
No dysplasia.
BN 1060 85 female 9mm chest junction nevus.
No dysplasia.
BN 1066 55 female 6mm chest junction nevus.
No dysplasia.
BN 1064 70 female 7mm upper leg junction nevus.
No dysplasia.
BN 5412 47 male 7mm back nevus with junction activity. 
No dysplasia.
M 1002 43 male 1.4mm Lower back nodular melanoma
M 1004 66 female 0.7mm Upper arm superficial spreading 
melanoma
M 1001 58 male 1.0mm Chest superficial spreading 
melanoma
M 1012 45 male 1.4mm Head nodular melanoma
M 1005 37 male 0.9mm Shoulder superficial spreading 
melanoma
M 1019 58 female 0.8mm Upper leg superficial spreading 
melanoma
M 1016 52 female 1.2mm Abdomen superficial spreading 
melanoma
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M 1007 57 female 0.8mm Elbow superficial spreading 
melanoma
M 1017 71 male 0.6mm Upper arm superficial spreading 
melanoma
M 1006 35 female 0.8mm Lower back superficial spreading 
melanoma
M 1000 51 female 0.8mm Shoulder superficial spreading 
melanoma
M 1010 44 male 0.8mm Scalp superficial spreading 
melanoma
M 1023 48 female 2.6mm Lower leg nodular melanoma
M 1062 69 female 3mm upper arm superficial spreading 
melanoma
Supplemental figure 1 Absolute quantification of the p16-Leiden mutation in scar and common nevi 
from FAMMM syndrome patients. Fractional abundance of p16-Leiden mutation in three scar tissue 
samples and common nevi 5412 and 10542 from FAMMM syndrome patients. The fractional abundance 
was significantly higher than 50% in all benign lesions suggesting that this technique is not informative 
to precisely quantify the mutant cell fraction. Error bars represent 95% CIs based on Poisson statistics. 
Forward primer: CTGCTGCTGCTCCACG Reverse primer: ACCAGCGTGTCCAGGAAG p16-Leiden probe: 
ACTGCGCCGACCCGT wild-type probe: ACTCTCACCCGACCCGTG.
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Supplemental Figure 2 Absolute quantification of rs4745670-[A] in melanomas and common 
melanocytic nevi from FAMMM syndrome patients. Absolute quantification of a copy number control 
SNP, rs4745670, located within the intronic region of 9q and fractional abundance of [A] allele in 
informative (heterozygous for SNP) A) Primary melanoma lesions and B) Common melanocytic nevi. 
Error bars represent 95% CIs based on Poisson statistics.
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Supplemental Figure 3 Histological examination of common melanocytic nevi from p16-Leiden 
mutation carriers. H&E staining of common melanocytic nevi (1065, 1071 and 1067) from p16-Leiden 
mutation carriers that showed loss of wild-type CDKN2A allele (magnification= 100x).
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Analysis of CRISPR-Cas9 screens 





Targeting the MAPK signaling pathway has transformed the treatment of metastatic 
melanoma. CRISPR-Cas9 viability screens provide a genome-wide approach to 
uncover novel genetic dependencies. Here we analyzed recently reported CRISPR-
Cas9 screens comparing data from 28 melanoma cell lines and 313 cell lines of other 
tumor types in order to identify fitness genes related to melanoma. We found an 
average of 1,494 fitness genes in each melanoma cell line. We identified 33 genes 
inactivation of which specifically reduced the fitness of melanoma. This set of 
tumor type-specific genes includes established melanoma fitness genes as well 
as many genes that have not previously been associated with melanoma growth. 
Several genes encode proteins that can be targeted using available inhibitors. We 
verified that genetic inactivation of DUSP4 and PPP2R2A reduces the proliferation 
of melanoma cells. DUSP4 encodes an inhibitor of ERK, suggesting that further 
activation of MAPK signaling activity through its loss is selectively deleterious to 
melanoma cells. Collectively, these data present a resource of genetic dependencies 
in melanoma that may be explored as potential therapeutic targets.
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Early-stage cutaneous melanoma can be effectively cured by surgical removal, but 
once metastasized patient prognosis is poor [1]. Increased signaling activity of 
the mitogen-activated protein kinase (MAPK) pathway is a hallmark of melanoma 
and can be attributed to mutations in the BRAF, NRAS, KIT or NF1 genes. These 
oncogenic mutations commonly occur in the early stages of melanoma development 
[1, 2]. In patients with BRAF-mutant metastatic melanoma, targeted therapy using 
BRAF and MEK inhibitors can lead to significant tumor regression [3]. Almost 
invariably melanoma cells acquire resistance to these targeted treatments and 
disease relapse occurs. Consequently, there is a need to identify additional genetic 
dependencies that might serve as therapeutic targets in metastatic melanoma. 
The application of genome-wide screens in human cancer cell lines has the potential 
to identify genetic dependencies that may be targeted therapeutically [4, 5]. Genome 
editing with CRISPR-Cas9 technology has improved the identification of genetic 
dependencies due to its high precision and limited off-target effects. In CRISPR-
Cas9 dropout screens a population of cells is transduced with a pooled sgRNA 
library and following culture, selective depletion of sgRNAs is measured to identify 
genes associated with a growth disadvantage or lethal phenotype, designated as 
fitness genes [6, 7]. Core fitness genes are involved in essential cellular processes 
that human cells depend on for survival and proliferation. In addition, context-
dependent fitness genes are distinguished in that they may be specific for cell lineage 
or genotype. Recently, genome-wide CRISPR-Cas9 screens have been performed in a 
range of cancer cell lines, yielding cancer-specific fitness genes [8-13]. Importantly, 
the majority of cancer-specific fitness genes were found to be limited to only one or 
two tumor types [13]. Specific genetic dependencies in cancer cells may constitute 
targetable therapeutic vulnerabilities. The objective of this study was to identify 
novel genetic dependencies that may serve as potential therapeutic targets in 
melanoma cells through analysis of CRISPR-Cas9 screen data. Among the 33 fitness 
genes that we define in melanoma, there are multiple genes that have not previously 
been associated with melanoma growth, including inhibitors of MAPK signaling 
activity, that may potentially serve as therapeutic targets for melanoma. 
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MATERIAL AND METHODS
CRISPR-Cas9 screen data 
The generation of CRISPR-Cas9 screen data at Broad Institute, Cambridge 
Massachusetts, available online at https://depmap.org/ceres/, was described 
previously [14]. Briefly, 341 tumor cell lines including 28 melanoma lines were 
engineered to express Cas9 and subsequently screened using the human Avana4 
library composed of 70,086 sgRNAs, targeting 17,670 genes (4sgRNAs per gene) 
and 995 non-targeting control sgRNAs [15]. Cancer cell lines were transduced at 
a multiplicity of infection (MOI) of 0.3 to ensure that each cell expresses only 
one sgRNA. Genomic DNA was purified from transduced cells cultured under 
puromycin selection at day 1 and day 21 for next generation sequencing. The cell 
lines included in the screens expressed Cas9 and the sgRNA library used targeted 
the protein-coding genome [14]. 
Comparative analysis to determine melanoma fitness genes 
The CRISPRcleanR package was applied to process the CRISPR-Cas9-derived 
essentiality profiles and correct for copy number amplifications [16]. CRISPR-Cas9 
screen data were analyzed using an R implementation of the BAGEL (Bayesian 
Analysis of Gene Essentiality) algorithm, generating a scaled Bayesian Factor 
(BF) score per gene [13, 17]. A 5% False Discovery Rate (FDR) cut-off was applied. 
The mutation annotation for each melanoma cell-line was derived from the cell-
line encyclopedia (CCLE) [18]. Gene-level BFs were computed by calculating the 
average of the BFs across sgRNAs targeting a gene. This algorithm uses reference 
sets of predefined essential and non-essential genes. Each gene was assigned a 
scaled BF computed by subtracting the BF at the 5% FDR threshold (obtained from 
classifying reference essential/non-essential genes using BF rankings) from the 
original BF. Those genes with a statistically significant depletion at 5% FDR had 
a scaled BF above zero. Fitness genes were determined by comparing the average 
drop out of sgRNAs targeting the same gene, to that of reference essential and 
non-essential genes [13, 17]. Scaled BFs were binarized to 0 (scaled BF <0) and 
1 (>0). A Fisher’s Exact test was performed on a two-way contingency table of 
fitness and non-fitness genes with binarized scaled BF scores from melanoma 
and the other tumor cell lines with the resulting p-values corrected for multiple 
testing using the Benjamini-Hochberg procedure (adjusted p-value <0.01). Gene 
expression data for the 28 melanoma cell lines were available for analysis from 
the CCLE data portal. The datasets are available at https://data.broadinstitute.
org/ccle/CCLE_RNAseq_081117.rpkm.gct [18]. Protein interaction networks and 
pathway enrichment analyses were performed using STRING and Enrichr [19, 20]. 
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Cell culture, Cas9 and sgRNA lentiviral transduction for validation 
Human melanoma cell lines used for functional follow-up experiments were cultured 
in DMEM supplemented with 10% Fetal Bovine Serum (FBS), penicillin (100 I.U./mL)/
streptomycin (100 μg/mL) and Glutamax (Thermo Fisher Scientific, Waltham, MA). 
A375, IGR1 and WM983B melanoma cell lines were obtained from ATCC/Rockland 
(Manassas, VA/Gilbertsville, PA) and HEK293T cells were available from lab stocks 
(Chemical and Cell biology, LUMC). Cell lines were STR profiled, tested negative for 
mycoplasma and cultured in a humidified incubator at 37oC and 5% CO2. 
Lentivirus for stable Cas9-expressing cell lines was produced by transfecting 
pKLV2-EF1a-Cas9Bsd-W (Addgene #68343) into HEK293T cells together with 
packaging vectors (psPax2 and pMD2.G). For gene inactivation experiments, two 
sgRNA sequences per gene of interest were cloned into a plasmid DNA vector (U6-
sgRNA-PGKpuro-2A-BFP) from the Sanger CRISPR-Cas9 genome-wide arrayed 
sgRNA library (Supplemental Table 1) containing the puromycin-resistance gene 
for selection [21]. The sgRNAs used for validations differed from those used in 
the Broad Avana4 library to provide orthogonal validation. Lentivirus stocks were 
produced following transfections into HEK293T cells using polyethylenimine (PEI) 
[22]. Viral titers were determined by antigen capture ELISA measuring HIV p24 
(ZeptoMetrix Corp., New York, NY, USA). Following lentiviral transduction with 
the Cas9-expression vector to reach MOI of 3 (100% infection efficiency) in A375, 
IGR1 and WM983B cells, the Cas9-editing efficiency was tested [13]. Capillary 
sequencing analysis was performed using the human U6 promoter forward primer 
(GACTATCATATGCTTACCGT) to align the sgRNA sequence to the backbone vector 
LV04 (Sigma Aldrich, St. Louis, MO) and ensure that the sgRNA sequence was 
correct. For lentiviral transductions with sgRNA-expression vectors, 105 cells were 
seeded in 6-well plates or 2.5x105 cells in 6 cm dishes. Cells were transduced next 
day in 2 ml or 5 ml culture medium supplemented with 8 μg/ml polybrene to reach 
MOI of 3. Cells were incubated overnight at 37oC and cultured for 4 days in fresh 
medium supplemented with blasticidin-S (5μg/ml) and puromycin (2μg/ml) for 
selection and further analysis. 
Immuno-blotting analysis
A375-Cas9, IGR1-Cas9 and WM983B-Cas9 cells were transduced with lentiviral 
sgRNA expression vectors and cell lysates were prepared for immunoblot analysis 
as described previously [23]. Antibodies used for detection included anti-DUSP4 
(1:1000), anti-PPP2R2A (1:1000), anti-BRAF(1:1000) (Cell Signaling Technology, 
Danvers, MA), and anti-Vinculin (1:1000, clone hVIN-1, Sigma-Aldrich, St. Louis, 
MO) as a loading control. Secondary anti-mouse and anti-rabbit antibodies were 
used at 1:10,000 (Jackson ImmunoResearch Europe, Ely, UK).
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Colony formation assays
After puromycin selection, following transduction with sgRNA expression vectors, 
the A375-Cas9, IGR1-Cas9 and WM983B-Cas9 cells were trypsinized, counted and 
seeded in triplicate in 12-well plates; 500 cells/ml (A375), 2000 cells/ml (IGR1) and 
3000 cells/ml (WM983B) for colony formation assays. Cells were fixed for 5-10 
minutes in 4% paraformaldehyde (PFA) and stained for 30 minutes with crystal 
violet (0.05%) when control wells transduced with negative control sgRNAs targeting 
SSX3 reached 80% confluency. Scanned images of the wells were obtained before 
solubilization of retained dye with 100% methanol to measure absorbance at OD540. 
Cell confluency assay
IGR1-Cas9 and A375-Cas9 cells were seeded in 96-well plates to monitor cell 
confluency using the IncuCyte live-cell analysis system (Essen BioScience, Ann 
Arbor, MI). For this assay, cells were seeded at a density of 50 cells/well (A375) and 
200 cells/well (IGR1) in 6 replicates and scanned images of each well were taken 
every 12 hours. Data were analyzed using IncuCyte software and confluency was 
calculated over 6 days (A375) and 8 days (IGR1) and normalized to the confluency on 
day 1 to correct for seeding variation. Colony formation and cell confluency assays 
were performed in biological duplicates and combined data were analyzed using 
GraphPad Prism version 8 (GraphPad software, San Diego, CA). A 2-way ANOVA 
and Bonferroni’s multiple comparisons test were performed to detect statistically 
significant differences in cell confluency (p-value<0.01). 
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CRISPR-Cas9 screen analysis for fitness genes in melanoma
To identify genes that are specifically required for viability of melanoma cells, data 
available from CRISPR-Cas9 screens performed at the Broad Institute (Cambridge, 
Massachusetts) were extensively processed and analyzed. In these genome-wide 
CRISPR-Cas9 dropout screens the depletion of sgRNAs from a genome-wide library 
was measured in populations of Cas9-expressing tumor cells following 21 days of 
culture after transduction [14]. Fitness genes were determined by comparing the 
average dropout of sgRNAs targeting the same gene to the profile of reference essential 
and non-essential genes using a supervised approach called BAGEL [13, 17]. Of all 
targeted genes 4,423 (25%) negatively affected the fitness of one or more melanoma cell 
lines. We found an average of 1,494 fitness genes in each of the 28 melanoma cell lines. 
There were 1,396 genes that reduced the fitness in half or more of the melanoma cell 
lines, a number similar to what was reported for other cancer types [13]. Our analysis 
yielded 193 genes that reduced fitness in all melanoma cell lines, 175 of which (91%) had 
been found to be core fitness genes in the haploid cell line HAP1 and are therefore not 
specific to melanoma (Supplemental Table 2) [24]. 
To identify tumor type-specific genetic dependencies for melanoma, we performed 
comparative analysis of the scaled BFs representing fitness effects for each gene in the 
28 melanoma cell lines and in the 313 cell lines from 18 other tumor types analyzed in 
parallel in the CRISPR-Cas9 screens [13, 14]. CRISPR-mediated inactivation of 33 genes 
was significantly associated with reduced fitness in melanoma when compared to tumor 
cell lines from other lineages after multiple testing correction (Figure 1A). The average 
median FPKM value of 31 genes was 14,606 (average Q1= 9,997 and average Q3= 20,103) 
with the exception of a few (Supplemental Figure 1). All BRAF-mutant melanoma cell 
lines showed reduced survival upon targeting of BRAF. The screen identified melanoma 
fitness genes having an effect size similar to BRAF, including CHMP4B, FERMT2, and 
DUSP4, supporting their potential as therapeutic targets (Figure 2). Of the 28 melanoma 
cell lines, 22 harbored BRAF V600 mutations, 4 harbored oncogenic NRAS mutations, 
one was NF1 mutant (in the absence of BRAF or NRAS mutations) and the remaining was 
triple-wildtype. There were no KIT mutations in any of the tested melanoma cell lines 
(Figure 2). This set of fitness genes related to melanoma included melanocyte-specific 
transcription factors such as MITF and SOX10, established as fitness genes for cells of the 
melanocytic lineage (Figure 1B, Supplemental Table 3) [25, 26]. A second cluster of fitness 
genes related to melanoma consisted of components of the MAPK signaling pathway, 
such as BRAF and MAPK1 (Supplemental Table 3). The finding of these established fitness 
genes in this gene set confirms the sensitivity of the CRISPR-Cas9 screen analysis. 
A third group of genes, to which MDM2 belongs, is involved in regulating p53 activity 
(Supplemental Table 3). For several genes, a role in melanoma progression has been 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Moreover, activation of AHR was recently reported to promote resistance to BRAF-
inhibitors in melanoma [28]. In addition, a set of fitness genes related to melanoma 
with undefined roles in melanocyte biology or melanoma pathogenesis was identified, 
such as MTMR6 and CRTC3. Pharmacological compounds are available that may halt 
melanoma growth for the products of 12 of the identified fitness genes related to 
melanoma, including AHR and MDM2 (Supplemental Table 3). 
Negative regulators of MAPK signaling are essential in melanoma
Remarkably, the identified MAPK signaling genes encoded not only activating but 
also inhibitory components such as DUSP4 and PEA15. DUSP4 dephosphorylates 
ERK1/2, in addition to p38 and JNK (Supplemental Table 4) [29]. While PEA15 is 
a negative regulator of MAPK signaling that acts by sequestering ERK1/2 in the 
cytoplasm [30]. The protein phosphatase PPP2R2A has pleiotropic functions, 
including regulation of ERK1/2 and AKT phosphorylation and is involved in double 
strand DNA repair (Supplemental Table 4) [31-34]. As melanoma is characterized 
by activation of MAPK signaling due to mutations in BRAF, NRAS, NF1 and KIT 
genes, this suggests that further hyperactivation of MAPK signaling through loss of 
inhibitors of this signaling pathway may be deleterious to melanoma cells. Based on 
their melanoma specificity (p-value), effect size (scaled BF score) and gene function 
we proceeded with functional in vitro studies of two genes encoding for proteins 
with inhibitory effect on MAPK signaling activity, DUSP4 and PPP2R2A. DUSP4 was 
a significant fitness gene in 16 melanoma cell-lines including one NRAS mutant and 
PPP2R2A significantly affected fitness of 16 melanoma cell-lines, including one NRAS 
mutant and one NF1 mutant (Figure 2). DUSP4 and PPP2R2A were homogenously 
expressed among the 28 melanoma cell-lines and transcript levels did not provide an 
explanation for the difference in sensitivity to inactivation– this might imply post-
translational factor influence on the function of these genes. 
Figure 3 Validation of PPP2R2A and DUSP4 knockout on proliferation of IGR1 and A375 cutaneous 
melanoma cell lines. a) Immunoblot analysis of BRAF, PPP2R2A and DUSP4 protein expression 4 days 
post-transduction with sgRNA expressing lentiviruses in IGR1 and A375 cells. Expression of vinculin 
was investigated as a loading control. b) Crystal violet images of a control depletion (SSX3), BRAF 
and two independent sgRNAs for PPP2R2A and DUSP4 in IGR1 and A375 cells. c) Comparison of two 
independent techniques, live cell imaging in 96-well plates and cell viability assay in 12-well plates for 
different knockout IGR1 and A375 lines. A 2-way ANOVA and Bonferroni’s multiple comparisons test was 
performed between the two techniques (*p<0.01). Error bars represent SE. d) Graphical representation 
of cell proliferation up to 8-days post seeding of IGR1 cells and 6-days post seeding of A375 cells. 
sgCtrl represents depletion of SSX3, BRAF depletion was used as a positive control and 2 independent 
sgRNAs were used for PPP2R2A and DUSP4. The normalized confluency (%) of IGR1 and A375 cells was 
corrected based on day 1 measurements. A 2-way ANOVA and Bonferroni’s multiple comparisons test 
was performed between the control and all other lines (*p<0.01). 
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We used CRISPR-mediated inactivation of the non-fitness gene SSX3 as a negative 
control and as the cell lines used for validation were BRAF-mutant, inactivation 
of BRAF was used as a positive control. First, we analyzed the effects of depletion 
of the candidate genes in the BRAF-mutant melanoma cell line WM983B, which 
was included in the CRISPR-Cas9 screen. Proteins encoded by the target genes 
BRAF, PPP2R2A and DUSP4 were significantly depleted by CRISPR-Cas9-mediated 
inactivation using two independent sgRNAs, as was confirmed by immunoblot 
analysis four days after transduction (Supplemental Figure 2A). The sgRNAs against 
BRAF also led to a decrease in DUSP4 protein levels, in accordance with regulation 
of DUSP4 by MAPK signaling as part of a negative feedback loop [29]. Upon CRISPR-
mediated inactivation of DUSP4 and PPP2R2A, a significant effect on WM983B cell 
viability was observed as measured using the crystal violet assay (Supplemental 
Figure 2B). Loss of proliferation caused by DUSP4-mediated depletion was similar to 
BRAF-mediated depletion in WM983B cells (Supplemental Figure 2C). The effects of 
inactivation of PPP2R2A using both sgRNAs was slightly less pronounced in this cell 
line. Combined, these data suggest that genetic depletion of DUSP4 and PPP2R2A 
has a significant effect on the proliferation of WM983B cells. 
Next, we examined the effects of PPP2R2A and DUSP4 depletion in two additional 
melanoma cell lines, both harboring BRAF mutations. Whereas the IGR1 melanoma 
cell line was also included in the CRISPR-Cas9 screens, the A375 melanoma cell line 
was not. Immunoblot analysis confirmed depletion of PPP2R2A and DUSP4 upon 
sgRNA transduction (Figure 3A). We could verify that PPP2R2A inactivation affects 
the viability of IGR1 cells 8 days after seeding according to the colony formation assay 
(Figure 3B), in accordance with results from CRISPR-Cas9 screen analysis. When 
monitoring cell confluency over time we observed decreased proliferation upon 
PPP2R2A inactivation in IGR1 cells, in line with the colony formation data (Figure 
3C and D). As for the independent A375 cell line, significant loss of viability was 
confirmed upon inactivation of DUSP4 and PPP2R2A through the colony formation 
assay (Figure 3B and C) and by normalized cell confluency over time (Figure 3D). 
Loss of proliferation upon CRISPR-Cas9-medicated inactivation of PPP2R2A was 
stronger when compared to DUSP4 depletion using both sgRNAs in A375 cells. 
One sgRNA targeting BRAF was more effective than the other in reducing cell 
viability and proliferation in all tested BRAF-mutant cell lines (Figure 3). Further 
studies are needed to unravel the nature and mechanism of the effects underlying 
these genetic dependencies. Decreased protein levels of DUSP4 and PPP2RA were 
detected in all melanoma cell lines by immunoblot analysis up to 10 days after 
transduction (Supplemental figure 3) confirming the effects of DUSP4 and PPP2RA 
on cellular fitness in melanoma cell lines. This suggests dependency of genes 
encoding inhibitors of oncogenic kinome signaling for proliferation. 
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Here, we present the results of analysis of genome-wide CRISPR-Cas9 screens 
aimed at identifying genes that melanoma cells depend on for fitness. The 
comparative analysis of the effects on fitness of gene inactivation in melanoma 
cells and other cancer cell lines uncovered a set of 33 fitness genes related to 
melanoma. We verified the fitness effects of PPP2R2A and DUSP4 in multiple 
melanoma cell lines. Genetic inactivation of several fitness genes had a similar 
effect on melanoma cell proliferation as BRAF inactivation. 
Strengths of this study are the sensitivity and robustness of the CRISPR-Cas9 
screening methodology by targeting the full human genome using an average of 
4 sgRNAs per gene and data analysis through normalization of copy-number-
associated effects, as well as comparative analysis of genetic dependencies in 28 
melanoma cell lines with those of 313 other tumor cell lines. Evaluation of CRISPR-
Cas9 screens in human melanocytes would have allowed further delineation of 
genes that are essential in melanoma from lineage-specific fitness genes, but 
such data are not yet available. As our identified hits include the melanocytic 
lineage transcription factors MITF and SOX10, it is probable that some of the 
other genes affect melanocyte fitness as well. Eleven of the identified 33 genes 
have been previously identified as fitness genes in haploid, CML-derived HAP1 
cells (BRAF, MAPK1, ZEB2, TCEB3, FERMT2, PPP2R2A, BPTF CHMP4B, INTS12, 
FBXW11 and COASY) [24]. Inactivation of these genes is significantly more 
detrimental to melanoma cells than to other tumor cell types, but they are likely 
to be involved in essential cellular processes [24]. The composition of the fitness 
gene set related to melanoma may be determined in large part by dependencies 
associated with mutant BRAF. In a previous study, gene dependency associations 
with BRAF mutation have been identified in 16 cancer types [8]. Mutant BRAF was 
present in nine of 146 of cancer cell lines and this oncogenic mutation was found 
to be associated with dependency on 50 genes in these cancer types. Many of the 
identified fitness genes such as NFATC2 and EGLN1 have an as yet undetermined 
role in melanoma biology. For 12 proteins encoded by genes identified as essential 
in the present study pharmacological compounds are available, implying that 
certain existing drugs might be efficacious in the treatment of melanoma.
We demonstrate genetic dependency on multiple MAPK signaling components in 
melanoma. Interestingly, these are not only activators but also inhibitors of MAPK 
signaling, such as DUSP4, and PEA15. In accordance with our findings, it has been 
reported previously that ERK1 and ERK2 overexpression results in cell death in 
BRAF and NRAS mutant melanoma cells [35]. Our results support the notion that 
further activation of MAPK signaling through loss of these inhibitors in melanoma 
cells that already harbor activating BRAF or NRAS mutations is detrimental, a 
104
hypothesis that will need to be explored with further experiments. Most melanoma 
cell lines included in the CRISPR-Cas9 screens carried the BRAF mutation, but 
screen data suggested that some NRAS-mutant melanoma cells might also be 
sensitive to inactivation of DUSP4 and PPP2R2A. Targeting these proteins may 
provide an alternative approach to treatment of metastatic melanoma, particularly 
after relapse from immunotherapy. It would be interesting to investigate whether 
BRAF-mutant melanoma cells that have acquired resistance to BRAF and MEK 
inhibitors remain sensitive to inhibition of PPP2R2A and DUSP4. Acquisition of 
resistance to BRAF inhibitors commonly involves reactivation of MAPK signaling. 
Discontinuation of BRAF inhibitor treatment in resistant melanoma cells results 
in hyperactivated MAPK signaling which may be detrimental to these cells [36, 
37]. DUSP4 depletion was recently reported to diminish the negative effects on 
melanoma cell viability induced by MEK inhibitors through increasing MAPK 
activity [38]. We hypothesize that once melanoma cells have acquired resistance to 
treatment with BRAF and MEK inhibitors by upregulation of MAPK activity they 
will become more sensitive to DUSP4 inhibition. Targeting negative regulators of 
MAPK signaling inhibitors such as DUSP4 and PEA15 could further activate MAPK 
signaling and may therefore be particularly effective in eliminating melanoma cells 
that have acquired resistance to BRAF and MEK inhibition. Alternate treatment 
with BRAF inhibitors and inhibitors targeting negative regulators of MAPK 
signaling could constitute an effective treatment strategy. The lack of specific 
pharmacological inhibitors for DUSP4 and PEA15 currently limits the possibility 
to determine those effects. 
Genetic inactivation of DUSP4 significantly reduced proliferation in a melanoma 
cell line that was included in the CRISPR-Cas9 screens (WM983B) as well as an 
independent melanoma cell line (A375). This suggests that DUSP4 could be an 
effective target across a larger panel of melanoma cell lines. Consistent with 
findings from the CRISPR-Cas9 screens, inactivation of DUSP4 did not induce a 
growth disadvantage in the IGR1 cell line, showing heterogeneity between different 
melanoma cell lines with respect to fitness effects. In addition not only BRAF 
mutant but some NRAS mutant melanoma cell lines were sensitive to inhibition of 
DUSP4 and PPP2R2A. PPP2R2A was confirmed to be a fitness gene in the two cell 
lines included in the initial CRISPR-Cas9 screens, IGR1 and WM983B as well as 
in the independent A375 cell line. PPP2R2A is a PP2A regulatory subunit that has 
been reported to inhibit MAPK signaling by dephosphorylating ERK [39], but also 
to promote MAPK signaling by regulating RAF and KSR [40, 41]. The PP2A complex 
has broader cellular functions, including regulation of oxidative stress signaling 
and DNA repair response [32, 33, 42, 43]. DUSP4 regulates phosphorylation of p38, 
JNK and other proteins in addition to ERK [44]. We have not investigated whether 
the fitness effects of DUSP4 and PPP2R2A are strictly dependent on their function 
as inhibitors of oncogenic kinome signaling.
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The generation of effective treatment strategies in melanoma remains a challenge. 
Here, we present an analysis of CRISPR-Cas9 screen data aimed at melanoma cell 
lines, identifying 33 genes that specifically affect the fitness in this tumor type. 
In vitro experiments in human melanoma cell lines confirmed that inactivation of 
DUSP4 and PPP2R2A results in decreased cell proliferation. Collectively, these data 
present a resource of genetic dependencies in melanoma that may be explored as 
potential therapeutic targets. 
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Supplemental Figure 2 Depletion of PPP2R2A and DUSP4 has a significant effect on WM983B 
proliferation. a) Immunoblot analysis of BRAF, PPP2R2A and DUSP4 protein expression 4 days post-
transduction with sgRNA expressing lentiviruses. Expression of vinculin was investigated as a loading 
control. b) Crystal violet images of a control depletion (SSX3), BRAF and two independent sgRNAs for 
PPP2R2A and DUSP4. c) Graphical representation of cell viability in WM983B cells 10-days post seeding. 
sgCtrl represents depletion of SSX3, BRAF depletion was used as a positive control and 2 independent 
sgRNAs were used for PPP2R2A and DUSP4. Experiments were performed in two biological replicates and 
in Figures 3-5 we show results of a representative experiment. A 2-way ANOVA and Bonferroni’s multiple 
comparisons test was performed between the control and all other lines (*p<0.01). Error bars represent SE.
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Supplemental Figure 3 Immuno-blot analysis of tested melanoma cell lines. Immuno-blot analysis of 
BRAF, PPP2R2A and DUSP4 protein expression 10 days post-transduction in all tested melanoma cell 
lines (A375, IGR1, WM983B). Expression of vinculin was investigated as a loading control.
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Supplemental Table 3 Description of 33 significant fitness genes in melanoma







TCEB3 Elongin A Increases the RNA polymerase II 
transcription elongation
NO NO
ARHGAP11A Rho GTPase Activating 
Protein 11A
Regulates p53-dependent cell-cycle 
arrest and apoptosis
NO NO
MITF Melanocyte Inducing 
Transcription Factor
Transcription factor that regulates the 
expression of genes with essential roles 
in cell differentiation, proliferation and 
survival
YES NO
NFATC2 Nuclear Factor Of 
Activated T Cells 2
Inducible expression of cytokine genes 
in T-cells
YES YES
GTF2H5 General Transcription 
Factor IIH Subunit 5
General and transcription-coupled 
nucleotide excision repair (NER) of 
damaged DNA
NO NO
SOX10 SRY-Box Transcription 
Factor 10
Involved in the regulation of embryonic 
development and in the determination 
of the cell fate.
NO YES
DUSP4 Dual Specificity 
Phosphatase 4
Negative regulation of members of 
the mitogen-activated protein (MAP) 
kinase superfamily
NO NO
TFAP2A Transcription Factor 
AP-2 Alpha
Transcription factor that binds the 
consensus sequence 5’-GCCNNNGGC-3’
NO NO
PPP2R2A Protein Phosphatase 
2 Regulatory Subunit 
Balpha
Ser/Thr phosphatase, implicated in 





E3 ubiquitin ligase, promotes tumor 
formation by targeting P53
YES YES





PEA15 Proliferation And 
Apoptosis Adaptor 
Protein 15
Negative regulator of apoptosis NO NO
PAX3 Paired Box 3 Transcription factor that may regulate 
cell proliferation, migration and 
apoptosis. 
YES NO
MUC12 Mucin 12, Cell Surface 
Associated
Integral membrane glycoprotein, 




Essential component of the MAP kinase 
signal transduction pathway
YES YES
FERMT2 Fermitin Family 
Member 2
Scaffolding protein that enhances 
integrin activation 
NO NO
BRAF B-Raf Proto-Oncogene, 
Serine/Threonine Kinase
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RFWD2 COP1 E3 Ubiquitin 
Ligase
Mediates ubiquitination and 
subsequent proteasomal degradation 
of target proteins
NO YES
ZEB2 Zinc Finger E-Box 
Binding Homeobox 2
DNA-binding transcriptional repressor 
that interacts with activated SMADs
NO NO
COASY Coenzyme A Synthase Coenzyme A (CoA), Important role in 
metabolic pathways 
NO YES
MTMR6 Myotubularin Related 
Protein 6
Phosphatase that acts on lipids with a 
phosphoinositol headgroup
NO YES
PPM1G Protein Phosphatase, 
Mg2+/Mn2+ 
Dependent 1G
Member of the PP2C family of Ser/
Thr protein phosphatases, negative 
regulator of cell stress response 
pathways
NO NO
IRF4 Interferon Regulatory 
Factor 4
IRF family of transcription factors, 
negatively regulates Toll-like-receptor 
(TLR) signaling
YES NO
CHMP4B Charged Multivesicular 
Body Protein 4B
Member of the chromatin-modifying 
protein/charged multivesicular 
body protein (CHMP) protein family, 
probable core component of the 
endosomal sorting 
NO NO
INTS12 Integrator Complex 
Subunit 12
Mediates 3-prime end processing of 
small nuclear RNAs U1
NO NO
FAM25C Family With Sequence 
Similarity 25 Member 
C
Protein coding gene, unknown 
interaction network
NO NO
AHR Aryl Hydrocarbon 
Receptor
Ligand-activated transcriptional 
activator Involved in the regulation of 
biological responses to planar aromatic 
hydrocarbons.
NO YES
TXNL1 Thioredoxin Like 1 Protein coding gene, unknown 
interaction network
NO NO
CRTC3 CREB Regulated 
Transcription 
Coactivator 3




Protein Kinase Kinase 
2
Dual specificity protein kinase, activates 
MAPK1/ERK2 and MAPK2/ERK3
YES YES
SOX9 SRY-Box Transcription 
Factor 9
Transcriptional regulator that plays a 
role in chondrocytes differentiation and 
skeletal development
NO NO
EGLN1 Egl-9 Family Hypoxia 
Inducible Factor 1
Catalyzes the post-translational 
formation of 4-hydroxyproline in 
hypoxia-inducible factor (HIF) alpha 
proteins, cellular oxygen sensor
NO YES
BPTF Bromodomain PHD 
Finger Transcription 
Factor



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The studies in this thesis explored several aspects of genetic dependencies in the 
development of familial and sporadic melanoma. CDKN2A is the most common 
high-penetrance susceptibility gene responsible for up to 40% of melanoma families 
worldwide. Interestingly, more than half of germline variation in familial predisposition 
to melanoma remains to be determined. To identify novel high-penetrance melanoma 
susceptibility genes we applied Whole Exome Sequencing (WES) and co-segregation 
analysis in a Dutch melanoma family. We identified NEK11 as a candidate high-
penetrance melanoma susceptibility gene and performed functional characterization 
in cancer cell lines to show loss-of-function (chapter 2). Our additional focus of 
investigation was a specific cohort of familial melanoma patients carrying a CDKN2A 
founder mutation, a 19-bp deletion known as the p16-Leiden mutation. Due to the 
variability in occurrence of pancreatic cancer (PC) and melanoma within familial 
melanoma families, we sought to examine genetic modifiers predicting the risk of PC 
and melanoma (chapter 3). In this specific cohort of familial melanoma patients, the 
timing of CDKN2A wild-type allele loss in melanoma development is unknown. We 
have applied a customized SNP-based digital PCR (dPCR) methodology to precisely 
quantify CDKN2A allelic imbalance depicting loss-of-heterozygosity (LOH) and 
attempted to deduce the order of genetic events based on absolute quantification of 
mutations and losses (CDKN2A LOH, BRAFV600E, TERT promoter, chromosome 9q LOH) 
(chapter 4). Finally, in addition to high-penetrance genes in familial melanoma, there 
are genes that are important fitness factors for cancer cell growth and may provide 
insight into the biology and progression of sporadic melanoma. The application of 
screening technologies has been successful in identifying genetic dependencies that 
could possibly be implemented as therapeutic targets in cancer. We have therefore 
analyzed Clustered Regular Interspaced Short Palindromic Repeats (CRISPR-Cas9) 
screening data to identify fitness genes in melanoma and used in-vitro systems to 
validate our findings (chapter 5). Combined, we hope to have uncovered novel genetic 
dependencies that could be used in the targeted treatment of sporadic as well as 
familial melanoma. 
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NEK11 AS A NOVEL HIGH PENETRANCE MELANOMA 
SUSCEPTIBILITY GENE
Even though CDKN2A is responsible for melanoma predisposition in a large subset 
of familial kindreds, the underlying genetic cause in approximately 50% of families 
remains unknown [1, 2]. Identification of high-penetrance genes is important, 
since germline mutation carriers can be enrolled in targeted cancer surveillance 
programs. The implementation of WES and WGS analyses has been instrumental 
in the identification of novel germline variants causing predisposition to 
melanoma [3-7]. In chapter 2, application of WES analysis in a Dutch melanoma 
family, identified a nonsense variant in the checkpoint regulatory gene, NEK11 
(p.R374X) co-segregating among affected family members. We showed LOH in 
a melanoma tissue sample of a NEK11 mutation carrier and expressed mutant 
NEK11 to study protein levels and function in cancer cell-lines. We demonstrated 
reduced levels of the truncated NEK11 protein caused by proteasomal degradation, 
suggesting loss-of-function through protein instability [8]. Combined, genetic 
and functional analysis of NEK11 p.R374X suggest a candidate high penetrance 
melanoma susceptibility gene.
Figure 1 Updated diagram of candidate high penetrance melanoma susceptibility genes. The diagram 
is adapted using data from chapter 2 to show the small contribution of the identification of NEK11 as a 
candidate high penetrance melanoma susceptibility gene
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Since, NEK11 emerged in a single Dutch-melanoma family it may only add to the 
current knowledge of germline variation within a small subset of melanoma families 
(Figure 1). The data might still provide valuable information for geneticists to include 
NEK11 in gene panel testing in order to identify more individuals at increased 
risk. In a recent study, >300.000 UK WES data sets from healthy volunteers were 
analyzed for non-synonymous protein truncating variants (PTVs) and no mutations 
were identified in NEK11, further supporting an extremely rare variant [9]. Moreover 
the NEK11 locus is not frequently deleted in melanoma according to TCGA data 
suggesting that the truncating mutation identified here is a rare event. This is 
supported by the absence of any NEK11 mutation in a recent multi-gene panel test 
of 488 Dutch familial melanoma cases [10]. Variants in the NEK11 gene, or perhaps 
other components of the pathways it is involved with, should be examined in large 
cohorts of familial melanoma cases, that are not explained by other established 
melanoma susceptibility genes to confirm the effect size of this variant [11]. 
NEK11 truncating variant expression and melanoma development 
The functional validation and mechanism of tumor development caused by PTVs is 
equally important to the initial implementation of sequencing technologies and analysis 
[12, 13]. This information can assist in improving mutation screening and personalized 
medicine in high risk patients. Our functional validation analysis demonstrated loss-of-
function of the NEK11 truncating variant through protein instability.
To investigate the role of NEK11 on cell proliferation and sensitivity to (UV) 
irradiation we attempted to knock-down NEK11 in melanoma and human 
osteocarcoma cells with shRNAs expressed from lentiviral vectors. However, 5 out 
of 5 different shRNAs were not effective, therefore this approach was stopped. 
Ideally, in the instance of a successful NEK11 knock-down system, a zebrafish 
model would be an informative method to test if knocking-out NEK11 in a BRAF 
and/or TP53 mutant background accelerates melanoma formation.
It has been shown that NEK11 is important for DNA damage induced (i.e. IR irradiation 
and irinotecan treatment) G2/M checkpoint arrest (Figure 2) [14-16]. It is possible, that 
NEK11 loss, caused by the loss-of-function mutation p.R374X, can result in genomic 
instability which might lead to the selection of cells with increased and uncontrolled 
proliferation (Figure 2). Therefore, mutation carriers might be more predisposed to 
melanoma than to other ‘internal’ cancer types because of more exposure to UV light. 
We did not see any differences between the two transfection conditions (NEK11 wild-
type and mutant) even when exposing cancer cells to UV radiation. Since the NEK11 
p.R374X protein is only expressed at very low levels, one would not expect an effect of 
expressing this construct in cells. Our results indicate that the p.R374X mutation in 
NEK11, resulting in truncation and destabilization of the protein is a loss-of-function 
mutation, which will result in reduced DNA damage-induced cell cycle checkpoints. 
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Based on the restriction of WES analysis to investigate only the coding part of 
the genome, the next step towards a better understanding of predisposition to 
melanoma is the employment of whole-genome sequencing (WGS) technology 
[17]. The identification of germline variants within the promoter region of TERT 
suggests that there is more to uncover from the non-coding part of our genome. 
Moreover, hereditary epigenetic alteration through DNA methylation is an 
additional mechanism regulating gene expression and silencing that deserves 
further investigation in future studies [18].
Collectively, our data present NEK11 as a very good candidate high penetrance 
melanoma susceptibility gene. Further investigation in more families world-wide 
is required to prove the significance of this candidate gene. Ultimately, in the 
near future, NEK11 may be added in clinical genetic testing high-risk melanoma 
families in order to improve patients’ surveillance. 
Figure 2 Proposed model of NEK11 truncating variant function in melanoma development. NEK11 
is an essential component of the G2/M checkpoint arrest pathway. Following DNA damage, CHK1 is 
activated through ATR kinases, leading to phosphorylation and activation of NEK11 which in turn leads 
to degradation of CDC25A and G2 arrest. The p.R374X mutation encodes for a truncated NEK11 protein. 
NEK11 loss would make a cell more prone to accumulate UV-induced DNA damage by stimulating 
CDC25A activation and cell cycle progression into mitosis (Figure is adapted from [15]).
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GENETIC DEPENDENCIES IN HEREDITARY MELANOMA 
CAUSED BY CDKN2A (P16-LEIDEN) MUTATION 
Since the discovery of CDKN2A as the first high-penetrance melanoma susceptibility 
gene, a plethora of scientific literature reported on the effect size of CDKN2A 
in familial predisposition to melanoma [19-21]. This dominant high penetrance 
melanoma susceptibility gene encodes for p16INK4A and p14ARF tumor suppressor 
proteins regulating the G1/S cell cycle checkpoint and p53-dependent pathways 
respectively [22]. Germline CDKN2A mutation carriers have approximately 70% 
risk of developing melanoma and an absolute risk of about 15-20% to develop PC 
[23-25]. A recent study has also shown that these melanoma-prone families should 
be screened at an early age for additional types of cancer other than melanoma 
and PC [26, 27]. Moreover, CDKN2A not only has a significant causative effect 
on familial predisposition to melanoma but is also a key tumor suppressor gene 
acting in the transition stage of invasive melanoma. Bi-allelic loss of CDKN2A 
distinguishes precursor lesions from invasive melanoma in sporadic cases [28]. 
We attempted to identify genetic modifiers predicting the risk of cancer in familial 
melanoma patients and investigated the timing of wild-type CDKN2A inactivation 
in the development and progression of hereditary melanoma. 
Genetic modifiers predicting the risk of PC and melanoma in 
CDKN2A mutation carriers
Clinical studies have shown variability in occurrence of PC and melanoma within 
CDKN2A-mutated families, suggesting that modifying factors have a significant role 
in determining the risk of developing these cancers [23]. The most well-known genetic 
modifier for melanoma development in CDKN2A mutation carriers is MC1R [29, 30]. 
Despite the significant effort in scientific literature to identify genetic modifiers for 
PC development in families there are still no definitive correlations identified [31, 32].
In chapter 3 we tested a variable genomic region within the TERT/CLPTM1L multi-
cancer risk locus that has been significantly correlated to PC risk in the general 
population [33]. Remarkably at the same time, carriers of the variant allele are at 
diminished risk of developing melanoma. In the current study, we applied SNP-
genotyping through the rhAMP-SNP-genotyping assay that uses reporter dyes 
suitable for a real-time PCR format and provide a quick and efficient method to 
genotype multiple samples simultaneously. Unfortunately, we did not find any 
significant association of the variant allele presence with PC risk in p16-Leiden 
carriers. A significant protective effect was observed for melanoma, similar to the 
general population, although the observed association was no longer significant 
after exclusion of probands to assess possible influence of ascertainment [34]. 
Combined, we did not find a significant association of the variant allele presence 
with PC or melanoma risk in p16-Leiden carriers. The low statistical power of our 
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study might be a limiting factor in identifying a significant effect but we cannot 
exclude the possibility that other PC or melanoma-associated SNPs that were not 
genotyped in this study might modify cancer risk in familial melanoma patients.
A study that used next-generation sequencing data to examine multiple high-risk 
PC-related genes in melanoma-prone families, identified nominal correlation with 
variants of mismatch repair genes (MLH1, MSH2, MSH6, PMS2), however, there 
were no loss-of-function mutations identified and only a subset of alterations 
was classified as potentially deleterious [32]. It has also been reported that 
environmental risk factors such as smoking, significantly modifies the risk of PC 
development in p16-Leiden mutation carriers [27]. The possibility of a combination 
of genetic and/or environmental risk factors of PC and melanoma in familial 
melanoma patients can therefore not be excluded.
Combined, these data suggest that although there is variability in cancer occurrence 
in familial melanoma patients, we still cannot precisely predict patients at increased 
risk using a strong genetic marker other than a germline CDKN2A mutation. We 
may also speculate that genetic and/or environmental modifiers predicting the 
risk of PC and melanoma in the general population are distinct from modifiers 
in familial melanoma patients that are already predisposed to developing cancer. 
Remarkably, the reported modifier MC1R gene variants modify melanoma risk also 
in sporadic melanoma suggesting there may also be unknown common variants 
for familial and sporadic melanoma [13, 35]. Still, more scientific data and effort 
are required to uncover novel genetic and environmental modifiers that predict 
PC and melanoma risk in familial melanoma patients and specifically in p16-Leiden 
mutation carriers. Identification of these risk modifiers would ultimately allow 
clinical geneticists to come forward with a personal risk score in affected families 
and provide a more patient tailored surveillance program. 
CDKN2A LOH is an early event in familial melanoma patients with 
the p16-Leiden mutation
The genetic evolution of melanocytic neoplasia in sporadic cases has been reviewed 
intensively with CDKN2A loss being shown as a significant factor in invasive melanoma 
stages [28, 36-38]. Bi-allelic CDKN2A inactivation has been reported in a small subset 
of dysplastic nevi in the general population but never in common melanocytic nevi 
[39]. Nevertheless, studies have shown CDKN2A LOH at the primary melanoma and 
metastasis stage in germline CDKN2A mutation carriers [40, 41]. The timing however, 
of CDKN2A wild-type allele loss in familial melanoma patients is unknown.
Our general aim in chapter 4 was to investigate the timing of CDKN2A LOH in 
melanocytic lesions of familial melanoma patients carrying the p16-Leiden mutation. 
The application of digital PCR (dPCR) technology provided a breakthrough of absolute 
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quantification of allelic imbalance and mutations in tumors [42]. We provided absolute 
quantification data of allelic imbalance through a customized SNP-based dPCR 
analysis indicative of LOH [43]. This method was efficient and highly informative since 
our efforts to use the 19bp deletion of p16-Leiden as a target of amplification in Formalin 
Fixed Paraffin Embedded (FFPE) tissue material turned out to be troublesome due to 
the size difference of wild-type and mutant CDKN2A amplicon.
We showed for the first time, subclonal loss of wild-type CDKN2A in a subset of 
common melanocytic nevi with absence of cytonuclear or tissue architectural 
atypia. We further demonstrated that a higher cell fraction was affected by CDKN2A 
LOH in primary melanomas than CDKN2A LOH in nevi [43]. The quantitative 
conclusions could be drawn from extensive analysis of sensitive dPCR data. In 
addition, we attempted to deduce the order of genetic events in melanocytic 
neoplasia of familial melanoma patients through absolute quantification of 
the presence of BRAFV600E mutation, TERT promoter (pTERT) mutation and 
chromosome 9q loss. In nevi, we demonstrated that CDKN2A LOH occurred after 
the driver BRAFV600E mutation in subclones of cells, we found no mutation in 
pTERT and no disruption of chromosome 9q. In melanomas however, we showed 
that CDKN2A LOH was clonal to BRAF V600E in the tested lesions. There was also 
presence of pTERT mutation in melanomas and chromosome 9q loss (Figure 3). 
These data suggest genomic instability in melanomas, by additional deletions on 
the longer arm of chromosome 9 by using a single intronic marker within GNAQ. 
Deletions across chromosome 9 have been reported in familial and sporadic 
melanomas previously [44]. Frequent somatic mutations within GNAQ have been 
mainly reported for ocular/uveal melanoma but not for cutaneous melanomas 
[45, 46]. To investigate further the extent of deletions within chromosome 9 in 
familial melanoma patients, additional markers across chromosome 9q should be 
investigated. Still, our findings indicate that the loss of chromosome 9q could be 
regarded as an additional step in melanoma development.
The subclonal bi-allelic inactivation of CDKN2A in common nevi of p16-Leiden 
mutation carriers resembles the development of BAP1-inactivated melanocytic 
tumors in patients with BAP1-tumor predisposition syndrome [47]. Due to the 
fact that p16INK4A is not uniformly expressed in nevi and truncated p16INK4A protein 
encoded by mutant CDKN2A is recognized by most antibodies at the same level 
as p16INK4A wild-type protein, confirmation of p16INK4A loss was not possible at the 
protein level. In addition, we may also underestimate the functional inactivation 
of CDKN2A in familial melanoma since intragenic mutation and promoter 
hypermethylation of CDKN2A were not investigated in the current study.
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Our results revealed a distinct order of genetic events in familial melanoma from the 
genetic evolution of sporadic melanoma, precisely involving bi-allelic loss of CDKN2A in 
early precursor lesions of common nevi (Figure 3). The intermediate stage of dysplastic 
nevus and invasive stage of melanoma requires further investigation to have a complete 
picture about the order of genetic events in familial melanoma. This however, was 
not the initial scope of our analysis; we chose not to include dysplastic nevi due to the 
difficulty to distinguish from early-stage melanoma. Invasive melanoma lesions were 
not available for analysis from familial melanoma patients with the p16-Leiden mutation. 
With regards to TERT promoter mutation, in our study it was only found in primary 
melanomas although the possibility that it is present in precursor lesions cannot be 
excluded [38, 48]. The additional somatic mutations found in sporadic melanoma 
development such as NRAS, NF1, PTEN and TP53 were not investigated here. Our analysis 
Figure 3 Proposed model of genetic evolution of melanocytic neoplasia in familial melanoma patients 
with the p16-Leiden mutation. Proposed order of genetic events based on data from chapter 4. Bi-allelic 
CDKN2A inactivation was found in subclones of common nevus cells that were already affected by the 
initial BRAFV600E mutation. In melanomas, we found clonality of BRAFV600E with CDKN2A loss and presence 
of TERT promoter mutations (pTERT), similar to sporadic melanoma and additional loss of chromosome 
9q in sub-clones of cells. The dysplastic nevus and invasive melanoma stage requires investigation. 
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was restricted to CDKN2A, BRAF and TERT due to limited DNA available from FFPE 
tissue. Fresh-frozen material could be ideal in this type of investigation although our 
SNP-based dPCR technique was effective and informative in FFPE material.
Combined, we showed that the highly quantitative and robust application 
of dPCR could be used to deduce the order of genetic events in melanoma and 
possibly for other tumor types in future studies through quantification of allelic 
imbalance. Although bi-allelic CDKN2A loss cannot distinguish common nevi from 
melanomas in this specific cohort of familial melanoma patients, our data suggest 
that presence of pTERT mutation and 9q loss could serve as diagnostic markers 
distinguishing melanomas from common nevi in CDKN2A mutation carriers. We 
may also speculate that subclones of nevi with bi-allelic CDKN2A loss are prone to 
progress to melanoma. 
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IDENTIFICATION OF FITNESS GENES IN MELANOMA
In previous chapters we have studied intensively the genetic dependencies in 
familial melanoma. In a collaboration with the Welcome Trust Sanger Institute 
(Hinxton, United Kingdom) we have explored the genetic dependencies in sporadic 
melanoma development. Even though high-penetrance genes may explain the 
germline variation in familial cases, in sporadic cases there is a different set of 
important genetic dependencies, known as fitness genes, that have an effect on 
cancer cell growth and could potentially be used as therapeutic targets [49]. Despite 
the significant effort in developing novel treatment strategies for melanoma, most 
advanced cases show relapse upon treatment [50, 51].The application of CRISPR-
Cas9 screening technology has been a successful tool in identifying novel targets 
of therapy by high precision and limited off-target effects compared to RNA 
interference and previously used methodology [52-54].
In chapter 5, we aimed to analyze and process available CRISPR-Cas9 screening data 
to identify novel fitness or essential genes in melanoma that may provide possible 
alternative pathways to melanoma treatment. In this instance, we have analyzed 
fitness scores known as scaled Bayesian factors available from a negative selection 
screen performed by the Broad Institute [55]. The purpose of negative selection 
screens is to identify targets with a stimulatory effect on cell growth and survival 
[56]. Our data and analysis was based on scaled Bayesian factors from a total of 342 
cancer cell-lines, 28 of which were melanoma cell-lines. To identify targets specific 
for the melanoma sub-group we compared the scaled Bayesian factors of melanoma 
to the other cancer types including breast, lung, central nervous system, prostate 
and others. A more positive scaled Bayesian factor indicates higher confidence 
that a given gene’s knock-out causes a decrease in fitness but does not necessarily 
depict the severity of the phenotype [57]. Our analysis resulted in 33 genes that 
were significantly depleted in the melanoma cell lines but not in the other cancer 
types. Those were centered around three melanocytic/melanoma-specific clusters 
of genes confirming the specificity of our analysis. One cluster involved the known 
fitness genes for melanocytic lineage such as MITF and SOX10. A second group 
was centered around p53 responses to DNA damage with fitness genes such as 
MDM2. Thirdly, melanoma-specific essential genes encoding for MAPK signaling 
pathway components such as BRAF and MAPK1 were among the most significant 
hits further supporting the sensitivity of our CRISPR-Cas9 screening data. Among 
the significant hits, we did not only find known fitness genes for melanoma but 
also genes reported in general cancer-related pathways such as FERMT2 and AHR 
[50, 58]. Remarkably, inhibitory components of the MAPK pathway were identified 
to be significant fitness genes in melanoma such as DUSP4, PPP2R2A and PEA15 
[59-62]. Combined, our analysis of available CRISPR-Cas9 screening data provided 
a robust and sensitive output specific for melanoma dependencies. 
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Depletion of the MAPK-pathway negative feedback loop contributes 
to loss of viability in melanoma 
To validate our comprehensive analysis of CRISPR-Cas9 screening data we 
performed genetic depletion in vitro, using two cell lines that were part of the initial 
screen and one independent melanoma cell line. From our list of 33 significant 
genes, we selected those with the highest effect size (p-value, scaled Bayesian 
factor) but also functional significance and pathway enrichment. We tested the 
effect on cell viability upon genetic depletion using two independent sgRNAs and 
specifically focused on two candidate genes that encode for components of the 
MAPK pathway negative feedback loop, PPP2R2A and DUSP4.
The MAPK pathway is subjected to a number of negative feedback loops. These 
include direct phosphorylation of upstream components such as MEK1/2, RAF, 
SOS by ERK1/2 but also feedback regulators that inhibit ERK1/2 such as DUSP4 
and Sprouty proteins [63]. PPP2R2A has pleiotropic functions including regulation 
of ERK1/2 levels but also DNA repair response [61, 64, 65]. Our results showed that 
genetic depletion of PPP2R2A and DUSP4 had a pronounced effect on cell viability 
in melanoma cell lines. Combined, these data show that the CRISPR-Cas9 screen 
data could be validated through decreased cell viability caused by depletion 
of regulators of the MAPK pathway negative feedback loop (Figure 4). We also 
uncover PPP2R2A and DUSP4 as novel genetic dependencies suggesting that our 
list of 33 significant fitness genes is valid not only according to bioinformatic data 
and analyses but also due to functional assays. 
Genetic inhibition, using sgRNAs is a strong and precise method to ensure efficient 
knock-out of a target of interest with low off-target effects and may provide novel 
genetic vulnerabilities in melanoma [53]. The exact mechanism of depletion however, 
requires further investigation to provide evidence on functional significance, i.e 
through the effect on regulation of downstream targets (ERK1/2 is a downstream 
target for DUSP4) (Figure 4). An important remark is to test the effect of PPP2R2A 
and DUSP4 depletion on a BRAF inhibitor resistant background to confirm the 
significance of candidate hits as novel alternative therapeutic targets.
The results of this CRISPR-Cas9 screen analysis may be applied in different 
mutation backgrounds including NRAS and BRAF. Interestingly, PPP2R2A and 
DUSP4 were significant fitness genes in two NRAS mutant cell lines that were 
included in the CRISPR-Cas9 screen, 21 BRAF mutant and one NF1 mutant. This 
suggests that PPP2R2A and DUSP4 may be fitness genes in an NRAS-mutant 
background although loss of viability has been confirmed only in BRAF mutant 
cell lines. Our effort to perform additional analysis for identifying fitness genes 
specific for an NRAS mutant background was restricted by the low statistical 
power of the different groups, therefore we could not make statistically significant 
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conclusions. The inclusion of more melanoma cell-lines, preferably NRAS mutant, 
since these tumors have high metastatic and resistance rates, would ultimately 
confirm the importance of candidate fitness genes identified here in patients 
showing resistance to MEK inhibitor therapy. A recent study using genome-wide 
CRISPR screen data identified FBXO42 to be involved in resistance towards MEK 
inhibition in NRAS mutant melanoma [66]. Moreover, the comparison of CRISPR-
Cas9 screening data of fitness genes between melanoma and melanocytes, instead 
of cancer cell lines from different tissue types, would enable us to eliminate 
lineage-specific dependencies. Future studies should also be implementing mouse 
models to test whether knocking out essential genes mediates tumor reduction 
in-vivo with limited side-effects. Combined, our extensive analysis and validation 
of CRISPR-Cas9 screen data uncovered two negative regulators of the MAPK 
pathway, PPP2R2A and DUSP4 as novel dependencies in melanoma although the 
mechanism of depletion requires further investigation. 
Figure 4 Depletion of MAPK-pathway negative feedback loop contributes to loss of viability in 
melanoma. Adapted model of negative feedback regulation of the MAPK pathway [63] . In chapter 5 
we analyzed CRISPR-Cas9 screen data and identified DUSP4 and PPP2R2A as significant fitness genes 
in melanoma. Depletion of DUSP4 and PPP2R2A resulted in significant loss of cell viability although the 
mechanism of depletion has not been studied yet. Here, we show a proposed example of the mechanism 
of depletion of the MAPK-pathway negative feedback loop components such as DUSP4, that may result 
in hyperactivation of ERK1/2 and contribute to loss of viability in melanoma cells. 
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CONCLUDING REMARKS AND FUTURE DIRECTIONS
This thesis aimed at uncovering novel genetic dependencies in familial and 
sporadic melanoma. Due to the high percentage (50%) of un-explained germline 
variation in familial predisposition to melanoma, we sought to identify novel high 
penetrance melanoma susceptibility genes. In chapter 2 we applied WES analysis 
in a Dutch family with melanoma and uncovered a novel germline nonsense 
variant in the checkpoint regulatory gene NEK11. We confirmed LOH in the 
melanoma tumor of a mutation carrier and represent a potential loss-of-function 
mutation through protein instability. Future studies should aim in confirming 
the importance of NEK11 as a candidate high-penetrance melanoma susceptibility 
gene in melanoma families world-wide and ultimately include NEK11 in clinical 
genetic testing to improve patients’ surveillance. In chapter 3 we searched for 
genetic modifiers predicting the risk of PC and melanoma in p16-Leiden carriers 
and found no significant association of a multi-cancer risk locus within TERT/
CLPTM1L and PC development. A significant negative association was observed 
with melanoma development, however there was an influence of ascertainment 
in our sample group and statistical significance was lost. Combined, these data 
suggest that genetic modifiers predicting the risk of PC and melanoma in familial 
melanoma patients with the p16-Leiden mutation remain to be determined. This 
information is important for melanoma and PC-prone p16-Leiden families to 
precisely predict individual’s personal risk of cancer development and possibly 
come forward with more patient tailored surveillance programs. Moreover, in 
the same cohort of familial melanoma patients, we investigated the sequence of 
CDKN2A inactivation events using FFPE-derived melanocytic lesions. In chapter 4, 
we show for the first time CDKN2A LOH as an early event in common melanocytic 
nevi via the application of SNP-based dPCR technology to precisely quantify 
allelic imbalance. We further show that while in nevi CDKN2A LOH occurs after 
the driver BRAFV600E mutation, in melanomas there is clonality between CDKN2A 
LOH with BRAFV600E mutation. Additional genetic alterations including presence 
of pTERT mutation and chromosome 9q loss were found only in melanoma lesions 
suggesting that these events could serve as markers for diagnosing melanoma in 
the tested cohort of familial melanoma patients. Remarkably, our data support 
that the sequence of CDKN2A inactivation in familial melanoma is distinct from 
melanocytic neoplasia in sporadic cases. The possibility of complete chromosome 
9 loss in melanomas also deserves further investigation to better understand 
the sequence of events in the genomic evolution of hereditary melanoma. Nevi 
with bi-allelic CDKN2A inactivation in familial melanoma patients may be more 
prone to progress into melanomas. Our data suggest that p16-Leiden carriers may 
undergo stricter surveillance programs starting from their benign nevi and not 
even atypical or dysplastic nevi. Our quantitative data of allelic imbalance may 
have a wider application in determining the genomic evolution of melanoma 
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but also of other tumor types in future studies. Lastly, in chapter 5 we explicitly 
focused on the identification of novel genetic vulnerabilities in melanoma 
development through the analysis of genome-wide CRISPR-Cas9 screening 
technology. Our comprehensive analysis identified 33 significant fitness genes 
specific for melanoma and not for other cancer types. Interestingly, among those 
hits we have identified regulators of the MAPK pathway negative feedback loop. 
Functional validation analysis in melanoma cell lines confirmed that genetic 
depletion of PPP2R2A and DUSP4 induced a pronounced effect on melanoma cell 
viability suggesting that CRISPR-Cas9 screening technology and data may uncover 
novel fitness genes in melanoma. The identification of MAPK pathway negative 
feedback loop as a novel vulnerability in melanoma has a major clinical implication 
as a potential therapeutic target. Future studies are needed to validate further 
the precise mechanism of these genetic vulnerabilities in suppressing metastatic 
melanoma growth and possibly limiting tumor relapse.
Combined, we have investigated thoroughly the genetic dependencies in familial 
and sporadic melanoma development and propose future studies that may 
ultimately improve clinical management and surveillance of melanoma patients. 
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Cutaan melanoom (CM) ontwikkelt zich door maligne ontaarding van melanocyten, 
de pigment-producerende cellen van de huid. CM is een van de dodelijkste vormen 
van huidkanker vanwege het vermogen van tumorcellen om uit te zaaien. Er 
worden naar schatting wereldwijd 232.100 gevallen per jaar gediagnosticeerd en 
er zijn ongeveer 55 500 sterfgevallen. Hoofdstuk 1 van dit proefschrift geeft een 
algemene introductie over de verschillende aspecten van genetische predispositie 
bij familiair melanoom en verkregen genetische veranderingen die ten grondslag 
liggen aan de ontwikkeling van melanoom.
Het voorkomen van melanoom bij familieleden is geassocieerd met verhoogd 
individueel risico op het ontwikkelen van deze vorm van huidkanker. Bij ongeveer 
10% van de patiënten met melanoom zijn ook familieleden aangedaan. Er wordt 
van familiair (of erfelijk) melanoom gesproken bij voorkomen van tenminste drie 
gevallen van melanoom in een familie waarvan twee of meer bij eerstegraads 
verwanten. In de jaren 90 werden erfelijke veranderingen in het CDKN2A gen 
geïdentificeerd als oorzaak van familiale clustering van melanoom. In Nederlandse 
families met melanoom betreft het doorgaans een specifieke ‘founder’ mutatie in 
CDKN2A , de p16-Leiden mutatie. Sinds de identificatie van CDKN2A zijn andere 
genen gerapporteerd als melanoom risico genen als oorzaak van familiair 
voorkomen, waaronder CDK4, BAP1, MITF, TERT, POT1, ACD, TERF2IP, GOLM1, 
EBF3, POLE en TP53AIP1. Erfelijke veranderingen in CDKN2A en deze andere genen 
verklaren tezamen minder dan de helft van de familiair melanoom gevallen; in 
meer dan 50% van de patienten met familiair melanoom is de oorzaak onbekend. 
In hoofdstuk 2 hebben we getracht de genetische basis van familiair melanoom te 
verhelderen door een erfelijke verandering in het NEK11 gene te onderzoeken. Deze 
erfelijke verandering was ontdekt bij alle door melanoom aangedane leden van 
een Nederlandse familie door toepassing van volledige exome sequencing (WES) 
-analyse. We toonden somatisch verlies van het wildtype allel (LOH) in het melanoom 
van een NEK11-mutatiedrager aan. Met behulp van experimenten met gekweekte 
cellen konden we aantonen dat de erfelijke verandering in het NEK11 gen, dat een 
rol speelt bij regulatie van de celcyclus, instabiliteit van het NEK11 eiwit waarvoor 
dit gen codeert veroorzaakt. De erfelijke verandering in het NEK11 gen leidt tot 
functieverlies en dit ondersteunt de hypothese dat erfelijke veranderingen in het 
NEK11 gen een oorzaak kunnen zijn van verhoogd risico op melanoom. 
CDKN2A is het meest voorkomende melanoom risico gen en belangrijkste oorzaak 
van familiair melanoom. Dragers met erfelijke CDKN2A mutaties hebben een risico 
van 70% om gedurende het leven melanoom te ontwikkelen en daarbij een risico 





Interessant is dat klinische studies variabiliteit suggereren in het voorkomen van 
melanoom en PC binnen families, hetgeen suggereert dat modificerende factoren 
kunnen bijdragen aan het risico van het ontwikkelen van deze twee tumortypen bij 
dragers van CDKN2A mutaties. Bepaling van erfelijke factoren die het risico op PC 
en melanoom in families met CDKN2A mutatie moduleren zou daarom een  betere 
identificatie mogelijk maken van patiënten met een extra verhoogd risico die baat 
zouden kunnen hebben bij gepersonaliseerde screening en preventie. In hoofdstuk 
3 hebben we getracht erfelijke factoren te identificeren die verantwoordelijk 
zijn voor het PC-risico in p16-Leidse families. We testten een Single Nucleotide 
Polymorphism (SNP) gelegen in een multi-kanker risico locus, TERT / CLPTM1L, en 
vonden geen significant verband met het PC risico. Met betrekking tot melanoom 
vonden we wel een significant beschermend effect van de SNP, hoewel er een 
invloed was op de vaststelling in onze testgroep van patiënten en na correctie 
was de waargenomen associatie niet langer significant. Onze studie geeft aan dat 
meer onderzoek nodig is om erfelijke factoren die het risico op PC en melanoom 
modificeren bij dragers van CDKN2A mutaties te bepalen.
Hoewel wetenschappelijke studies hebben aangetoond dat verlies van het tweede 
wildtype allel bij patiënten met familiair melanoom ten gevolge van een erfelijke 
mutatie in het CDKN2A gen essentieel is voor de ontwikkeling van invasief 
melanoom is het niet bekend in welke fase in de ontwikkeling van melanocyt, 
moedervlek (nevus) naar melanoom dit optreedt. In hoofdstuk 4 hebben we 
CDKN2A-inactivatie onderzocht door verlies van heterozygositeit (LOH) bij 
melanocytaire nevi en melanoom van patiënten met een erfelijke CDKN2A mutatie. 
Toepassing van gevoelige digitale PCR (dPCR)-technologie maakte nauwkeurige 
kwantificering van het CDKN2A gen mogelijk en toonde aan dat in een aantal 
melanocytaire nevi het wildtype CDKN2A-allel verloren ging in subklonen van 
cellen. Dit bracht ons tot de conclusie dat bij familiair melanoom bi-allelische 
inactivatie van het CDKN2A gen al in een vroeg, pre-maligne stadium kan optreden. 
Dit is anders dan wat bekend is over de genomische evolutie van sporadisch (niet-
familiair) melanoom. De kwantitatieve gegevens van dPCR-analyse van CDKN2A, 
BRAF, TERT en een locus op chromosoom 9q gaven ook inzicht in de volgorde waarin 
deze genetische verandering tijdens de vorming van melanoom optreden. Onze 
resultaten tonen aan dat BRAF mutatie optreedt vóór CDKN2A-verlies in het nevus 
stadium en verlies op chromosoom 9q later bij de ontwikkeling van melanoom. 
Het is aannemelijk dat melanocytaire nevi die subklonen bevatten van cellen met 
CDKN2A LOH een hoger risico hebben om zich te ontwikkelen tot melanoom.
Naast genen geassocieerd met risico om melanoom te ontwikkelen en genen die 
een oorzakelijke rol spelen bij de vorming van melanoom kan een andere klasse 
van melanoom fitness genen onderscheiden worden. Deze genen relevant voor 
de biologie en behandeling kunnen worden gebruikt als doelwit voor therapie en 
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vormen in zekere zin de Achilleshiel van tumorcellen. Identificatie is vooral van 
groot van belang om nieuwe aanknopingspunten voor therapie te ontwikkelen. 
Tegen veel van de huidige therapieen voor uitgezaaid melanoom worden deze 
tumoren namelijk resistent. In hoofdstuk 5 beschrijven we analyses, verricht 
in samenwerking met het Wellcome Trust Sanger Institute (VK), op functionele 
genoom-wijde CRISPR-Cas9 screen resultaten gericht op het vinden van melanoom 
fitness genen en daarmee kwetsbaarheden voor therapie. Eerder gerapporteerde 
fitnessgenen voor melanoom, zoals SOX10, BRAF en MITF behoorden tot de door 
ons geïdentificeerde genen; dit suggereert dat de resultaten van deze screen 
analyse specifiek zijn voor melanoom. Opvallend was dat inactivatie van genen die 
coderen voor eiwitten die het MAPK signaaltransductiepad remmen, zoals DUSP4 
en PPP2R2A, de celdeling van melanoomcellen blokkeerden. Dit kan erop wijzen 
dat deze fosfatase eiwitten geschikte doelen voor therapie van melanoom zouden 
kunnen zijn.
In hoofdstuk 6 bespreken we de bevindingen van dit proefschrift, beperkingen en 
suggereren toekomstige richtingen. Gezamenlijk hopen we door toepassing van 
nieuwe genomische technieken een stap vooruit te hebben gezet in het begrijpen 
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